Publikationen

Publikationen 2017

Publikationen 2017

Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer K-P, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G. Who is a ‘healthy subject’? – Consensus results on pivotal eligibility criteria for clinical trials. Eur J Clin Pharmacol 2017 Jan 7. doi: 10.1007/s00228-016-2189-8. epub ahead of print.

 

Doricakova A*, Theile D*, Weiss J*, Vrzal R*. Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4. Naunyn Schmiedebergs Arch Pharmacol 2017;390:49-59.

Faller CK, Lampert A, Haefeli WE, Seidling HM. Beitrag einer Servicestelle zur Sicherstellung der Rezeptqualität an einem Klinikum. Krankenhauspharmazie 2017;38:116.

Lampert A, Haefeli WE, Seidling HM. Zu Risiken und Nebenwirkungen lesen Sie die Packungsbeilage UND fragen Sie Ihren Arzt oder Apotheker. Krankenhauspharmazie 2017;38:110. 

Mayer T, Haefeli WE, Seidling HM. Vorgehen bei der Erkennung, Bewertung und Vermeidung anticholinerger Nebenwirkungen - eine Querschnittsbefragung unter Ärzten. Krankenhauspharmazie 2017;38:111.

Meid AD, von Medem A, Heider D, Adler J-B, Günster C, Seidling HM, Quinzler R, König HH, Haefeli WE. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf 2017;40:133-144.

 

Mikus G, Heinrich T, Bödigheimer J, Röder C, Matthee AK, Weiss J, Burhenne J, Haefeli WE. Semisimultaneous midazolam administration to evaluate the time course of CYP3A activation by a single oral dose of efavirenz.J Clin Pharmacol 2017.

 

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017;19:298-312. 


Morath B, Mayer T, Send A, Hoppe-Tichy T, Haefeli WE, Seidling HM. Pharmazeutisch beeinflussbare Risikofaktoren für Rehospitalisierungen oder unerwünschte Arzneimittelwirkungen nach Krankenhausentlassung - eine systematische Übersichtsarbeit. Krankenhauspharmazie 2017;38:111-112.

    

O’Brien T, Wells JCD, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, Mikus G, Morlion BJ, Perez-Cajaraville J, Pogatzki-Zahn E, Varrassi G. European Pain Federation (EFIC) position paper on appropriate opioid use in chronic pain management. Eur J Pain 2017;21:3-19. 

 
Send AFJ, Peters-Klimm F, Bruckner T, Haefeli WE, Seidling HM. A randomized controlled trial to assess the effect of a medication plan containing drug administration recommendations on patient’s drug knowledge after 2 months. J Clin Pharm Ther 2017;42:69-74.

 

Send AFJ, Ancker JS, Abramson E. Entwicklung einer Broschüre und eines Dosisrechners zur Unterstützung der Verabreichung von flüssigen Peroralia in der ambulanten pädiatrischen Versorgung in den USA. Krankenhauspharmazie 2017;38:113.


Theile D, Hohmann N, Kiemel D, Gattuso G, Barreca D, Mikus G, Haefeli WE, Schwenger V, Weiss J. Clementine juice has the potential for drug interactions - in vitro comparison with grapefruit and mandarin juice. Eur J Pharm Sci 2017;97:247-56.


Weißenborn M, Haefeli WE, Seidling HM. Entwicklung eines Handbuches zur Verbesserung der Zusammenarbeit zwischen Ärzten und Apothekern im ambulanten Bereich. Krankenhauspharmazie 2017;38:115.

 

 

In Press


Bock JO, Hajek A, Brenner H, Saum KU, Matschinger H, Haefeli WE, Quinzler R, Heider D, König HH. A longitudinal investigation of willingness to pay for health insurance in Germany. Health Serv Res 2017.

 

Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Meyer MR, Maurer HH, Halberstadt AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. Drug Test Anal 2017.

Hajek A, Bock JO; Brenner H, Saum KU, Matschinger H, Haefeli W, Quinzler R, Heider D, König HH. Welche Faktoren beeinflussen die privaten Zuzahlungen zu Gesundheitsleistungen im Alter? Ergebnisse einer Längsschnittstudie. Gesundheitswesen 2017.

 

Harnoss JM, Platzer LK, Burhenne J, Radhakrishnan P, Cai J, Strowitzki MJ, Weiss J, Ritter AS, Mollenhauer M, Schmidt T, Ulrich A, Haefeli WE, Schneider M. Prolyl hydroxylase inhibition enhances liver regeneration without induction of tumor growth. Ann Surg 2016 March 8. Epub ahead of print.

 

Heider D, Matschinger H, Meid AD, Quinzler R,  Adler JB, Günster C,  Haefeli WE, König HH. Health service use, costs and adverse events associated with potentially inappropriate medication in old age in Germany: retrospective matched cohort study. Drugs Aging 2017.  

       
Lampert A, Haefeli WE, Seidling HM. Reasons for drug administration problems and perceived needs for assistance of patients, family caregivers, and nurses: a qualitative study. J Patient Saf 2017.

 

Mayer T, Meid AD, Saum K-U, Brenner H, Schöttker B, Seidling HM, Haefeli WE. Comparison of nine instruments to calculate anticholinergic load in a large cohort of older outpatients: association with cognitive and functional decline, falls, and use of laxatives. Am J Geriatr Psychiatry 2017.
    

Meid AD, Groll A, Schieborr U, Walter J, Haefeli WE. How can we define and Analyse drug exposure more precisely to improve the prediction of hospitalizations in lonitudinal (Claims) data? EUR J Clin Pharmacol 2017. Epub ahead of print. 

Podszun MC, Jakobi M, Birringer M, Weiss J, Frank J. The long chain α–tocopherol metabolite α-13’-COOH and γ-tocotrienol induce P-glycoprotein expression and activity by activation of the pregnane X receptor in the intestinal cell line LS 180. Mol Nutr Food Res 2017.

  

Seidling HM, Send AF, Bittmann J, Renner K, Dewald B, Lange D, Bruckner T, Haefeli WE. Medication review in German community pharmacies - Post-hoc analysis of documented drug-related problems and subsequent interventions in the ATHINA-project. Res Social Adm Pharm 2017.

 

Send AFJ, Bittmann J, Dyckhoff G, Haefeli WE, Seidling HM. What do laypeople consider “medication,” and are they aware of modulators of a drug’s effects? Eur J Hosp Pharm 2017.

Schaefer N, Helfer AG, Kettner M, Laschke MW, Schlote J, Ewald AH, Meyer MR, Menger MD, Maurer HH, Schmidt PH. Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans? Drug Test Anal 2017.  

Vaughns JD, Ziesenitz VC, Williams EF, Mushtaq A, Bachmann R, Skopp G, Weiss j, Mikus G, van den Anker JN. Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery - a Pilot Study. Pediatr Drugs 2017.


von Medem A, Seidling HM, Eichler H-G, Kaltschmidt J, Metzner M, Hubert CM, Czock D, Haefeli WE. Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics. Eur J Clin Pharmacol 2017.

 
Weinheimer M, Fricker G, Burhenne J, Mylius P, Schubert R. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - an in vitro and in vivo comparison. Eur J Pharm Sci. 2017. Epub ahead of print.

Publikationen 2016

Publikationen 2016

Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, Hoffmann MM, Weiss J. SLCO1B1 gene variations among Tanzanians, Ethiopians and Europeans: Relevance for African and worldwide precision medicine. OMICS 2016;20:538-45.

Arana MR, Tocchetti GN, Rigalli JP, Mottino AD, Villanueva SS. Physiological and pathophysiological factors affecting the expression and activity of the drug transporter MRP2 in intestine. Impact on its function as membrane barrier. Pharmacol Res 2016;109:32-44.

 

Becker JP, Clemens JR, Theile D, Weiss J. Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assays. Anal Biochem 2016;509:124-9. 

 

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. Myrcludex B: a first-in-human clinical study with a first-inclass hepatitis B and hepatitis D virus entry inhibitor. J Hepatol 2016;65:483-489.

Blank A, Eidam A, Lampert A, Pathil-Warth A, Mikus G. Arzneimitteltherapie in der Schwangerschaft: Risiken und Chancen im klinischen Alltag einschätzen (Drugs in pregnancy: risks and opportunities in prescribing). Gastroenterologe.2016;4:323-331.

Bock JO, Heider D, Matschinger H, Brenner H, Saum KU, Haefeli WE, König HH. Willingness to pay for health insurance among the elderly population in Germany. Eur J Health Econ 2016;17:149-58.    

 

Bock JO, König HH, Brenner H, Haefeli WE, Quinzler R, Matschinger H, Saum KU, Schöttker B, Heider D. Associations of frailty with health care costs - results of the ESTHER cohort study. BMC Health Serv Res 2016;16:128-38.     

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients. J Hepatol 2016;65:490-498

Dettmer S, Theile D, Schäfer J, Seckinger A, Burhenne J, Weiss J. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. Naunyn Schmiedebergs Arch Pharmacol 2016;389:1091-1101.

Doering JH*, Lampert A*, Hoffmann GF, Ries M. Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions: a cross sectional analysis. PLoS One 2016, Aug 24;11(8):e0161660. doi: 10:1371/journal.pone.0161660.       

                               

Duysburgh E, Temmerman M, Yé M, Williams A, Massawe S, Williams J, Mpembeni R, Loukanova S,  Haefeli WE, Blank A. Quality of antenatal and childbirth care in rural health facilities in Burkina Faso, Ghana and Tanzania: an intervention study.Trop Med Int Health 2016;21:70-83.  

 

Enderle Y, Foerster K, Burhenne J. Clinical feasibility of Dried Blood Spots: analytics, validation, and applications. J Pharm Biomed Anal 2016;130:234-43. 

 

Faller CK, Haefeli WE, Seidling HM. How to move an elephant. Qualität der Rezepte in einem Universitätsklinikum und Konsequenzen für die öffentliche Apotheke. DAZ 2016;38:56-61.

Gade C, Mikus G, Christensen HR, Dalhoff KP, Holm JC, Holst H. The CYTONOX trial. Dan Med J 2016;63:A5226. 

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J. Long-term effect of rifampicin-based antiTB regimen co-administration on the pharmacokinetic parameters of efavirenz and 8-hydroxy-efavirenz in HIV infected and TB-HIV co-infected Ethopian patients. J Clin Pharmacol 2016;56:1538-49.

    

Hohmann, N, Maus A, Carls A, Haefeli WE, Mikus G:  St. John's Wort treatment in women bears risks beyond pharmacokinetic drug interactions. Arch Toxicol 2016;90:1013-1015.  

 

Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol 2016;12:479-97.

 

Hohmann N, Reinhard R, Schnaidt S, Witt L, Carls A, Burhenne J, Mikus G, Haefeli WE. Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. J Antimicrob Chemother 201;71(8):2241-7.


Hohmann N, Xia N, Steinkamp-Fenske K, Förstermann U, Li H. Estrogen receptor signaling and the PI3K/Akt pathway are involved in betulinic acid-induced eNOS activation. Molecules 2016;21:973.

Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, Mikus G. Dose-dependent bioavailability and CYP3A-inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet 2016;55:1535-45.

König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol 2016;77:413-27.

   

Lampert A, Hoffmann GF, Ries M. Ten Years after the International Committee of Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional Analysis. PLoS One 2016;11:e0144973.

Lampert A, Wien K, Haefeli WE, Seidling HM. Guidance on how to develop comprehensible patient information leaflets in four steps. Int J Qual Health Care 2016;28:634-638.

Londero AS, Arana MR, Perdomo VG, Tocchetti GN, Zecchinati F, Ghanem CI, Ruiz ML, Rigalli JP, Mottino AD, Garcia F, Villanueva SSM. Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats. J Nutr Biochem 2016;40:178-86.

Lutz T, Lampert A, Hoffmann GF, Ries M. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US Orphan Drug Act. Orphanet J Rare Dis. equal contribution.

Mächler S, Meid AD, Send AFJ, Quinzler R, Freigofas J, Haefeli WE. Vor dem Essen - zum Essen - nach dem Essen? Welche Rolle spielen Essenshinweise auf Medikationsplänen? DAZ 2016;22:58-65. 

Mächler S, Meid AD, Quinzler R, Haefeli WE. Ist mangelhafte Qualität von Medikationsplänen mit arzneimittelbezogenen Problemen assoziiert? Eine Pilotstudie. eHealth Journal 2016;1:26-31.

Mardal M, Miserez B, Bade R, Portolés T, Bischoff M, Hernández F, Meyer MR. 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. J Pharm Biomed Anal 2016;128:485-95.

Maurer HH, Meyer MR. High-resolution mass spectrometry in toxicology: current status and future perspectives. Arch Toxicol 2016;90:2161-72.

Mayer T, Kopitz J, Plaschke K, Weiss J, Seidling HM, Haefeli WE. Limitations of the anticholinergic activity assay and consequences for its clinical application. Am J Geriatr Psychiatry 2016;12:1182-8.
   
Meid AD, Haefeli WE. Age-dependent impact of medication underuse and strategies for improvement. Gerontology 2016;62:491-9.


Meid AD, Quinzler R, Groll A, Wild B, Saum K-U, Schöttker B, Heider D, König H-H, Brenner H, Haefeli WE. Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life. Eur J Clin Pharmacol 2016 Mar 29 epub ahead of print.

Meid AD, Heider D, Adler J-B, Quinzler R, Brenner H, Günster C, König H-H, Haefeli WE. Comparative evaluation of methods approximating drug prescription durations in claims data: Modeling, simulation, and application to real data. Pharmacoepidemiol Drug Saf 2016;25:1434-42.


Meyer GM, Maurer HH, Meyer MR. Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. Bioanalysis 2016;8:457-81.

Meyer MR. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Arch Toxicol 2016;90:2421-44.  

Meyer MR, Maurer HH. Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today? Anal Chim Acta 2016;927:13-20.  

Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem 2016;408:3571-91.

Meyer MR, Hübschmann HJ. Handbook of GC-MS: fundamentals and applications, 3rd ed. Anal Bioanal Chem 2016;408:1535-6.

 
Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New insights into drug-drug interactions and co-medication regimens. AAPS J 2016.


Muth C, Harder S, Uhlmann L, Rochon J, Fullerton B, Güthlin C, Erler A, Beyer M, van den Akker M, Perera R, Knottnerus A, Valderas JM, Gerlach FM, Haefeli WE. Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ Open 2016;6:e011613. 

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study. Medicine (Baltimore). 2016 Aug;95(34):e4631.

Outeiro N, Hohmann N, Mikus G. No increased risk of ketoconazole toxicity in drug-drug interaction studies. J Clin Pharmacol 2016;56:1203-1211.

 

Perdomo VG, Rigalli JP, Luquita MG, Pellegrino JM, Ruiz ML, Catania VA. Up-regulation of ATP-binding cassette transporters in the human macrophagic cell line THP-1 by the antichagasic benznidazole. Mem Inst Oswaldo Cruz 2016;111:707-11.

Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH. Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem 2016;408:6283-94.


Rigalli JP, Tocchetti GN, Arana RM, Villanueva SSM, Catania VA, Theile D, Ruiz ML, Weiss J. The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Letters 2016, epub ahead of print

 

Rigalli JP, Perdomo VG, Ciriaci N, Frances DE, Ronco MT, Bataille AM, Ghanem CI, Ruiz ML, Manautou JE, Catania VA. The tripanocidal Benznidazole promotes adaptive response to oxidative injury. Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2). Toxicol Appl Pharmacol 2016;304:90-8.

Rigalli JP, Ciriaci N, Mottino AD, Catania VA, Ruiz ML. Modulation of expression and activity of ABC transporters by the phytoestrogen genistein. Impact on drug disposition. Curr Med Chem 2016;23:1370-89.

Saum K-U, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, Brenner H. Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J AM Geriatr Soc 2016 Dec 26. doi:10/111/jgs.14718. epub ahead of print.  

  

Seidling HM, Faller CK, Thalheimer M, Bruckner T, Haefeli WE. Formal prescribing errors are substantially reduced in electronic prescribing and after teaching sessions. Dtsch Med Wochenschr 2016;141:e1-7. 

 

Seidling MH, Stützle M, Hoppe-Tichy T, Allenet B, Bedouch P, Bonnabry P, Coleman JJ, Fernandez-Llimos F, Lovis C, Rei MJ, Störzinger D, Taylor LA, Pontefract SK, van den Bemt PMLA, van der Sijs H, Haefeli WE. Best practice strategies to safeguard drug prescribing and drug administration – an anthology of expert views and opinions. Int J Clin Pharm 2016;38:362-73. 

Schmitt T, Mayer-Steinacker R, Mayer F, Grünwald V, Schütte J, Hartmann JT, Kasper B, Hüsing J, Hajda J, Ottawa G, Mechtersheimer G, Mikus G, Burhenne J, Lehmann L, Heilig C, Ho AD, Egerer G: Vorinostat in refractory soft tissue sarcomas - results of a multi-center phase II trial of the German Soft Tissue Sarcoma and Bone Tumor Working Group (AIO). Eur J Cancer 2016;64:74-82.

  
Stockklausner C*, Lampert A*,  Hoffmann GF, Ries M. Novel Treatments for Rare Cancers: The US Orphan Drug Act is Delivering. A Cross-Sectional Analysis. Oncologist 2016 Apr;21(4):487-93.

Theile D, Kos M. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. Toxicol Lett 2016;242:47-52.   

Tocchetti GN, Rigalli JP, Arana MR, Villanueva SS, Mottino AD. Modulation of expression and activity of intestinal multidrug resistance-associated protein 2 by xenobiotics. Toxicol Appl Pharmacol 2016;303:45-57.
 

Wagmann L, Meyer MR, Maurer HH. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 2016;258:55-70. 

Weiss J, Gajek T, Köhler B, Haefeli WE. Venetoclax (ABT-199) might act as a perpetrator in pharmacokinetic drug-drug interactions. Pharmaceutics 2016;8:5. 

Witt L, Suzuki Y, Hohmann N, Mikus G, Haefeli WE, Burhenne J. Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1027:207-13.

  

Publikationen 2015

Publikationen 2015

Boehlen F, Herzog W, Quinzler R, Haefeli WE, Maatouk I, Niehoff D, Saum KU, Brenner H, Wild B. Loneliness in the elderly is associated with the use of psychotropic drugs. Int J Geriatr Psychiatry 2015;30:957-64.

 

Campos B, Weisang S, Osswald F, Ali R, Sedlmeier G, Bageritz J, Mallm JP, Hartmann C, von Deimling A, Popanda O, Goidts V, Plass C, Unterberg A, Schmezer P, Burhenne J, Herold-Mende C. Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia 2015;63:1850-9.

 

Clemens J, Seckinger A, Hose D, Theile D, Longo M, Haefeli WE, Burhenne J, Weiss J. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemother Pharmacol 2015;75:281-91.

 

Czock D, Konias M, Seidling HM, Kaltschmidt J, Schwenger V, Zeier M, Haefeli WE. Tailoring of alerts substantially reduces the alert burden in computerized clinical decision support for drugs that should be avoided in patients with renal disease. J Am Med Inform Assoc 2015;22:881-7.

 

Czock D, Sommerer C. Niedermolekulare Heparine bei Niereninsuffizienz - Was ist bei der Anwendung zu beachten? Dialyse aktuell 2015;19:78-85.

 

Czock D, Spitaletta M, Keller F. Suboptimal antimicrobial drug exposure in patients with renal impairment. Int J Clin Pharm 2015;37(5):906-16.

 

Dettmer S*, Theile D*, Seckinger A, Burhenne J, Weiss J. Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity. Anal Biochem 2015;471:23-5.
*Equal contribution

 

Eichbaum C, Mathes K, Burhenne J, Markert C, Blank A, Mikus G. Pre-systemic Elimination of Tilidine: Localization and Consequences for the Formation of the Active Metabolite Nortilidine. Basic Clin Pharmacol Toxicol 2015;116:129-33.

 

Enderle Y, Meid A, Friedrich J, Grünig E, Wilkens H, Haefeli WE, Burhenne J. Dried blood spot technique for the monitoring of ambrisentan, bosentan, sildenafil, and tadalafil in patients with pulmonary arterial hypertension. Opens external link in new windowAnal Chem 2015;87:12112-20. IF: 5,636

 

Freigofas J, Seidling HM, Quinzler R, Schöttker B, Saum KU, Brenner H, Haefeli WE. Characteristics of medication schedules used by elderly ambulatory patients. Eur J Clin Pharmacol 2015;71:1109-20.

 

Haag M, Hofmann U, Mürdter TE, Heinkele G, Leuthold P, Blank A, Haefeli WE, Alexandrov A, Urban S, Schwab M. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na<sup>+</sup>-taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem 2015; 407:6815-25.

 

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics 2015;16:1047-64.

 

Haefeli WE. Arzneimitteltherapie bei betagten Patienten. Atemwegs- und Lungenkrankheiten 2015;1:21-6.

 

Hohmann N, Haefeli WE, Mikus G. Use of Microdose Phenotyping to Individualise Dosing of Patients. Clin Pharmacokinet 2015;54:893-900.

 

Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol 2015;79:278-285.

 

Keller F, Czock D. NephroPharmacology coming of age. Clin Nephrol 2015;84:127-9.

 

Keller F, Ludwig U, Czock D. Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. Expert Opin Drug Metab Toxicol 2015;11:139-47.

 

König HH, Lehnert T, Brenner H, Schöttker B, Quinzler R, Haefeli WE, Matschinger H, Heider D. Health service use and costs associated with excess weight in older adults in Germany. Age Ageing 2015;44:616-23.

 

Lohmann K, Ferber J, Haefeli M, Störzinger D, Schwald M, Haefeli WE, Seidling HM. Knowledge and training needs of nurses and physicians on unsuitable drugs for patients with dysphagia or feeding tubes. J Clin Nurs 2015;24:3016-9.

 

Lohmann K, Freigofas J, Leichsenring J, Wallenwein CM, Haefeli WE, Seidling HM. Development and evaluation of an algorithm to facilitate drug prescription for inpatients with feeding tubes. Eur J Clin Pharmacol 2015;71:489-97.

 

Lohmann K, Gartner D, Kurze R, Schösler T, Schwald M, Störzinger D, Hoppe-Tichy T, Haefeli WE, Seidling HM. More than just crushing: a prospective pre-post intervention study to reduce drug preparation errors in patients with feeding tubes. J Clin Pharm Ther 2015;40:220-5.

 

Markert C, Kastner IM, Hellwig R, Kalafut P, Schweizer Y, Hoffmann MM, Burhenne J, Weiss J, Mikus G, Haefeli WE. The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 Genotype. Basic Clin Pharmacol Toxicol 2015;116:423-8.

 

Mayer T, Haefeli WE, Seidling HM. Different methods, different results - how do available methods link a patient's anticholinergic load with adverse outcomes? Eur J Clin Pharmacol 2015;71:1299-314.

 

Meid AD, Lampert A, Burnett A, Seidling HM, Haefeli WE. The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysis. Br J Clin Pharmacol 2015;80:768-76.

 

Meid AD, Quinzler R, Freigofas J, Saum KU, Schöttker B, Holleczek B, Heider D, König HH, Brenner H, Haefeli WE. Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study. PLoS One 2015;10:e0136339.

 

Mensah N, Sukums F, Awine T, Meid A, Williams J, Akweongo P, Kaltschmidt J, Haefeli WE, Blank A. Impact of an electronic clinical decision support system on workflow in antenatal care: the QUALMAT eCDSS in rural health care facilities in Ghana and Tanzania. Glob Health Action 2015;8:25756.

 

Mikus G. Urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions? J Anal Toxicol 2015;39:81-2.

 

Mikus G, Klimas R. Relative contribution of morphine and morphine-6-glucuronide to the analgesic effect after morphine administration. Br J Anaesth 2015;114:1007.

 

Niemann D, Bertsche A, Meyrath D, Koepf ED, Traiser C, Seebald K, Schmitt CP, Hoffmann GF, Haefeli WE, Bertsche T. A prospective three-step intervention study to prevent medication errors in drug handling in paediatric care. J Clin Nurs 2015;24:101-14.

 

Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, Fabian J, Schober A, Fernekorn U, von Deimling A, Deubzer HE, Milde T, Witt O, Oehme I. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 2015;6:e1657.

 

Reuter T, Warta R, Theile D, Meid AD, Rigalli JP, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Dyckhoff G, Haefeli WE, Weiss J. Role of NR1l2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology 2015;388:1141-50.

 

Schiele JT, Penner H, Schneider H, Quinzler R, Reich G, Wezler N, Micol W, Oster P, Haefeli WE. Swallowing tablets and capsules increases the risk of penetration and aspiration in patients with stroke-induced dysphagia. Dysphagia 2015;30:571-82.

 

Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology 2015;4:e1001217.

 

Sukums F, Mensah N, Mpembeni R, Massawe S, Duysburgh E, Williams A, Kaltschmidt J, Loukanova S, Haefeli WE, Blank A. Promising adoption of an electronic clinical decision support system for antenatal and intrapartum care in rural primary healthcare facilities in sub-Saharan Africa: The QUALMAT experience. Int J Med Inform 2015;84:647-57.

 

Theile D, Allendorf D, Köhler BC, Jassowicz A, Weiss J. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in MDR cell lines. J Pharm Pharmacol 2015;67:1575-84.

 

Theile D, Haefeli WE, Weiss J. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine 2015;49:842-53.

 

Theile D, Weiss J. Comment on "Sweat but no gain": Inhibiting proliferation of multidrug resistant cancer cells with "Ersatzdroges". Int J Cancer 2015;136:2241-2.

 

Weiss J, Baumann S, Theile D, Haefeli WE. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan. Pulm Pharmacol Ther 2015;30C:80-86.

 

Weiss J, Haefeli WE. Comment on: Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. J Antimicrob Chemother 2015;70:322-3.

 

Ziesenitz VC, König SK, Mahlke N, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol 2015; 55: 708-717.

 

 

 

 

Book Chapters

Czock D, Keller F. Arzneimittelinduzierte Nephrotoxizität. In: Haase M, Haase-Fielitz A (Hrsg). Akute Nierenschädigung. 1. Auflage. Heidelberg: Springer; 2015. S. 117-31.

 

Czock D, Seidling S. Dosisanpassung bei Niereninsuffizienz. In: Rose O, Friedland K (Hrsg). Angewandte Pharmakotherapie. 1. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2015. S. 465-78. 

 

Haefeli, WE. Arzneimittel-Interaktionen in der pulmonalen arteriellen Hypertonie:Mechanismen, Ausmaß und Prävention.1. Auflage.Stuttgart:Verlag für Klinik und Praxis;2015

 

Seidling HM, Stuetzle M, Haefeli WE. Aufgaben des Medikamentenmanagements. In: Euteneier A (Hrsg). Handbuch Klinisches Risikomanagement. 1. Auflage. Heidelberg: Springer; 2015. S. 185-93.

 

Seidling HM, Stuetzle M, Haefeli WE. Aufgaben des Medikamentenmanagements. In: Euteneier A (Hrsg). Handbuch Klinisches Risikomanagement. 1. Auflage. Heidelberg: Springer; 2015. S. 516-20.

 

 

Publikationen 2014

Publikationen 2014

Albarmawi A*, Czock D*, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J, Ganten TM, Sauer P, Haefeli WE. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores. Br J Clin Pharmacol. 2014;77:160-9.
*Equal contribution

 

Ammenwerth E, Aly AF, Bürkle T, Christ P, Dormann H, Friesdorf W, Haas C, Haefeli WE, Jeske M, Kaltschmidt J, Menges K, Möller H, Neubert A, Rascher W, Reichert H, Schuler J, Schreier G, Schulz S, Seidling HM, Stühlinger W, Criegee-Rieck M. Zum Einsatz von Informationstechnologie zur Verbesserung der Arzneimitteltherapiesicherheit (Memorandum AMTS-IT). GMS Med Inform Biom Epidemiol. 2014;10(1):Doc03.

 

Ammenwerth E, Aly AF, Bürkle T, Christ P, Dormann H, Friesdorf W, Haas C, Haefeli WE, Jeske M, Kaltschmidt J, Menges K, Möller H, Neubert A, Rascher W, Reichert H, Schuler J, Schreier G, Schulz S, Seidling HM, Stühlinger W, Criegee-Rieck M. Memorandum on the use of information technology to improve medication safety. Methods Inf Med 2014;53:336-43.

 

Ammenwerth E, Aly AF, Criegee-Rieck M, Haefeli WE, Neubert A. Memorandum zum Einsatz von Informationstechnologie in der Arzneimitteltherapie: Herausforderungen und Empfehlungen. Z Evid Fortbild Qual Gesundhwes 2014;108:242-3.

 

Becker JP, Weiss J, Theile D. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation. Toxicol Lett 2014;225:43-7.

 

Bock JO, Matschinger H, Brenner H, Wild B, Haefeli WE, Quinzler R, Saum KU, Heider D, König HH. Inequalities in out-of-pocket payments for health care services among elderly Germans - results of a population-based cross-sectional study. Int J Equity Health 2014;13:3.

 

Birgersson S, Ericsson T, Blank A, Hagens Cv, Ashton M, Hoffmann KJ. A high-throughput LC-MS/MS assay for quantification of artesunate and its metabolite dihydroartemisinin in human plasma and saliva. Bioanalysis 2014;6:2357-69.

 

Carls A, Jedamzik J, Witt L, Hohmann N, Burhenne J, Mikus G. Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. Br J Clin Pharmacol 2014;78:1433-1440.

 

Carls A, Winter J, Enderle Y, Burhenne J, Gorenflo M, Haefeli WE. Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports. J Med Case Rep 2014;8:171.

 

Clemens J, Longo M, Seckinger A, Hose D, Haefeli WE, Weiss J*, Burhenne J*. Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr A 2014;1345:128-38.
* Equal contribution

 

Czock D. Antidiabetika bei Patienten mit Niereninsuffizienz. Der Nephrologe 2014;9:433-41.

 

Czock D, Keller F. Antibiotikadosierung bei Dialysepatienten. Der Nephrologe 2014;9:477-87.

 

Dalaba MA, Akweongo P, Williams J, Saronga HP, Tonchev P, Sauerborn R, Mensah N, Blank A, Kaltschmidt J, Loukanova S. Costs associated with implementation of computer-assisted clinical decision support system for antenatal and delivery care: case study of kassena-nankana district of northern ghana. PLoS One 2014;9:e106416.

 

Deppe S, Ripperger A, Weiss J, Ergün S, Benndorf RA. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan. Biochem Biophys Res Commun 2014;443:1211-7.

 

Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother 2014;69:1633-41.

 

Ericsson T, Blank A, von Hagens C, Ashton M, Abelö A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol 2014;70:1453-63.

 

Faller CK, Seidling HM, Haefeli WE. Gute Verordnungspraxis im ambulanten Sektor – Qualitätsanforderungen an die Rezeptschreibung in Deutschland. Ther Umsch 2014;71:317-23.

 

Freigofas J, Haefeli WE, Schöttker B, Brenner H, Quinzler R. Indirect evidence for proton pump inhibitor failure in patients taking them independent of meals. Pharmacoepidemiol Drug Saf 2014;23:768-72.

 

Freytag A*, Quinzler R*, Freitag M, Bickel H, Fuchs A, Hansen H, Hoefels S, König H-H, Mergenthal K, Riedel-Heller SG, Schön G, Weyerer S, Wegscheider K, Scherer M, van den Bussche H, Haefeli WE, Gensichen J,  für die MultiCare Study Group. Gebrauch und potenzielle Risiken durch nicht verschreibungspflichtige Schmerzmittel - Ergebnisse einer Beobachtungsstudie in der Primärversorgung. Schmerz 2014; 28:175-82.
* Equal contribution

 

Haefeli WE. Asthma und COPD im Alter - Das richtige Inhalieren muss trainiert werden. Der Allgemeinarzt 2014;10:34-6.

 

Haefeli WE. Polypharmazie und Arzneimitteltherapie im Alter. Eine Balance zwischen Einsetzen, Anpassen und Absetzen von Medikamenten. Klinikarzt 2014;43:404-9.

 

Haefeli WE, Carls A. Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol 2014;10:359-77.

 

Heider D, Matschinger H, Müller H, Saum KU, Quinzler R, Haefeli WE, Wild B, Lehnert T, Brenner H, König HH. Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. BMC Health Serv Res 2014;14:71.

 

Hohmann N, Halama B, Siller N, Mikus G, Haefeli WE. Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam. Clin Pharmacol Ther 2014;95:490-1.

 

Hohmann N, Mikus G, Czock D. Wirkungen und Risiken neuartiger psychoaktiver Substanzen: Fehldeklaration und Verkauf als „Badesalze“, „Spice“ und Forschungschemikalien“. Dtsch Ärzteblatt 2014;111:139-147.

 

Keller F, Hartmann B, Czock D. Time of effect duration and administration interval for sitagliptin in patients with kidney failure. Eur J Drug Metab Pharmacokinet 2014;39:77-85.

 

Klimas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth 2014;113:935-44.

 

Lampert A, Haefeli WE, Seidling HM. Do you have any questions about your medication? Patient Educ Couns 2014;97:434.

 

Lampert A, Seiberth J, Haefeli WE, Seidling HM. A systematic review of medication administration errors with transdermal patches. Expert Opin Drug Saf 2014;13:1101-14.

 

Lampert A*, Tesarz J*, Volkert A, Wesche D, Wild B, Schwab M, Haefeli WE. An N-of-1 trial as an individualized withdrawal treatment approach for psychological methylphenidate dependence. Psychother Psychosom 2014;83:379-81. equal contribution

 

Liu L, Detering J-C, Milde T, Witt O, Haefeli WE, Burhenne J. Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. J Chromatogr B 2014;964:212-21.

 

Lohmann K, Ferber J, Send AF, Haefeli WE, Seidling HM. Inappropriate crushing information on ward lists: cytotoxic drugs, capsules, and modified release formulations are gravely neglected. Eur J Clin Pharmacol 2014;70:565-73.

 

Loukanova S, Prytherch H, Blank A, Duysburgh E, Tomson G, Gustafsson LL, Sié A, Williams J, Leshabari M, Haefeli WE, Sauerborn R, Fonn S. Nesting doctoral students in collaborative North-South partnerships for health systems research. Glob Health Action 2014;7:24070.

 

Mahler C, Freund T, Baldauf A, Jank S, Ludt S, Peters-Klimm F, Haefeli WE, Szecsenyi J. Das strukturierte Medikamentenmanagement in der Hausarztpraxis - ein Beitrag zur Förderung der Arzneimitteltherapiesicherheit. Z Evid Fortbild Qual Gesundhwes 2014;108:258-69.

Mahlke NS, Ziesenitz V, Mikus G, Skopp G. Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Int J Legal Med 2014;128:771-8.

 

Markert C, Burhenne J, Weiss J, Mikus G, Haefeli W. CYP2C9 Polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Clin Pharmacol Ther 2014;95:250-1.

 

Markert C, Ngui P, Hellwig R, Wirsching T, Kastner IM, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. Influence of St. John's wort on the steadystate pharmacokinetics and metabolism of bosentan. Int J Clin Pharmacol Ther 2014;52:328-36.

 

Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel K-D, Burhenne J, Weiss J, Mikus G, Haefeli WE. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. Br J Clin Pharmacol 2014;77:141-8.

 

Markert C, Wirsching T, Hellwig R, Burhenne J, Weiss J, Riedel KD, Mikus G, Haefeli WE. Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. Int J Clin Pharmacol Ther 2014;52:957-64.

 

Mikus G, Klimas R. Contribution of oxycodone and its metabolites to the analgesic effect. Br J Anaesth 2014;112:944-5.

 

Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. J Antimicrob Chemother 2014;69:3311-9.

Niemann D, Bertsche A, Meyrath D, Oelsner S, Ewen AL, Pickardt B, Henhapl T, Hoffmann G, Meyburg J, Bertsche T. Drug Handling in a Paediatric Intensive Care Unit - Can Errors be Prevented by a Three-Step Intervention? Klin Padiatr 2014;226:62-67.

 

Phansalkar S, Zachariah M, Seidling HM, Mendes C, Volk L, Bates DW. Evaluation of Medication Alerts in Electronic Health Records for Compliance with Human Factors Principles. J Am Med Inform Assoc 2014;21:e332-40.

 

Rickert V, Haefeli WE, Weiss J. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro. Pulm Pharmacol Ther 2014;28:130-7.

 

Roggelin L, Pelletier D, Hill JN, Feldt T, Hoffmann S, Ansong D, Sylverken J, Burhenne J, Fischer-Herr J, Mehrfar P, Thiel C, Burchard GD, Nguah SB, Cramer JP. Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria. Malar J 2014;13:219.

 

Roos K, Gotthardt D, Giese T, Schnitzler P, Stremmel W, Czock D, Eisenbach C. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. Liver Transpl 2014;20:1106-17.

 

Schiele JT, Schneider H, Quinzler R, Reich G, Haefeli WE. Two techniques to make swallowing pills easier. Ann Fam Med 2014;12:550-2.

 

Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl le H, Mikus G, Burhenne J, Ho AD, Egerer G. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 2014;32:3413-20.

 

Seidling HM, Haefeli WE. Gute Verordnungspraxis. Ther Umsch 2014;71:313-6.

 

Seidling HM, Klein U, Schaier M, Czock D, Theile D, Pruszydlo MG, Kaltschmidt J, Mikus G, Haefeli WE. What, if all alerts were specific – estimating the potential impact on alert burden. Int J Med Inform 2014;83:285-91.

 

Seidling H, Lenssen R. Empfehlungen zur Arzneimitteltherapiesicherheit im Krankenhaus. Z Evid Fortbild Qual Gesundhwes 2014;108:44-8.

 

Send AFJ, Schwab M, Gauss A, Rudofsky G, Haefeli WE, Seidling HM. Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. Eur J Clin Pharmacol 2014;70:1243-50.

 

Seyffart G. Nephropharmakologie. Viele Daten ohne Sinn. Der Nephrologe 2014;9:427-32.

 

Siller N, Egerer G, Bochtler T, Hohmann N, Mikus G. Normal CYP3A activity during arsenic trioxide therapy. Ann Hematol 2014;93:1941-2.

 

Siller N, Egerer G, Weiss J, Mikus G. Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation. Arch Toxicol 2014;88:179-80.

 

Sukums F, Mensah N, Mpembeni R, Kaltschmidt J, Haefeli WE, Blank A. Health workers' knowledge of and attitudes towards computer applications in rural African health facilities. Global Health Action 2014;7:24534.

 

Theile D, Gal Z, Warta R, Rigalli JP, Lahrmann B, Grabe N, Herold-Mende C, Dyckhoff G, Weiss J. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biol Ther 2014;15:436-42.

 

Theile D, Mikus G. Deceptive argumentation against diagnostic microdosing of anticancer drugs. Int J Cancer 2014;135:1753-4.

 

Warta R*, Theile D*, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Weiss J, Dyckhoff G. Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. PLoS One 2014;9:e108908.
* Equal contribution

 

Weiss J, Becker JP, Haefeli WE. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but no PXR activator in vitro. Int J Antimicrob Agents 2014;43:184-8.

 

Weiss J, Theile D, Dvorak Z, Haefeli WE. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro. Pharmaceutics 2014;6:632-50.

 

 

Buchbeiträge

Freigofas J, Quinzler R, Kaltschmidt J, Haefeli WE, Saum KU. Medikationspläne im Alltag: Anforderungen, Nutzen und das ernüchternde Abbild in der Realität. In: Duesberg, F. Hellmann G (Hrsg). e-Health 2014: Solingen; S. 66-74.

 

Seidling HM, Haefeli WE. Erhöhung der Medikationssicherheit im Krankenhaus durch elektronische Verordnungsunterstützung. In:  Burgard G, Baberg HT, Popken G (Hrsg). Patientensicherheit GemeinsamSicher. 1. Aufllage. Berlin: MWV Medizinisch Wissenschaftliche Verlagsgesellschaft mbH & Co. KG; 2014. S. 91-7.

 

Stracke S, Czock D. Systematik des Nierenversagens. In: Hautmann R (Hrsg). Urologie. 5. Auflage. Heidelberg: Springer Medizin Verlag; 2014. S. 438-57.

 

Stützle M, Send AFJ, Mahler C, Längst G, Seidling HM, Haefeli WE. Nutzergruppen-spezifische Anforderungen an Struktur und Inhalt von Medikationsplänen. In: Duesberg, F. Hellmann G (Hrsg). e-Health 2014: Solingen; S. 24-9.

Publikationen 2013

Publikationen 2013

Bates DW, Baysari MT, Dugas M, Haefeli WE, Kushniruk AW, Lehmann CU, Liu J, Mantas J, Margolis A, Miyo K, Nohr C, Peleg M, de Quirós FGB, Slight SP, Starmer J, Takabayashi K, Westbrook JI. Discussion of "Attitude of physicians towards automatic alerting in computerzied physician order entry systems". Opens external link in new windowMethods Inf Med 2013;52:109-27.

 

Blank A, Prytherch H, Kaltschmidt J, Krings A, Sukums F, Mensah N, Zakane A, Loukanova S, Gustafsson LL, Sauerborn R, Haefeli WE. "Quality of prenatal and maternal care: bridging the know-do gap" (QUALMAT study): an electronic clinical decision support system for rural Sub-Saharan Africa. Opens external link in new windowBMC Med Inform Decis Mak 2013;13:44.

 

Böhnke E, Dietz L, Heinrich T, Aderjan R, Skopp G, Mikus G. Disposition and enterohepatic circulation of intravenously administered 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in serum and urine in healthy human subjects. J Forensic Toxicol Pharmacol 2013;2:2-6.

 

Carli-Ghabarou D, Seidling HM, Bonnabry P, Lovis C. A survey-based inventory of clinical decision support systems in computerized provider order entry in Swiss hospitals. Opens external link in new windowSwiss Med Week 2013;143:w13894.

 

Clemens KE, Faust M, Jaspers B, Mikus G. Pharmacological treatment of constipation in palliative care: A review. Opens external link in new windowCurr Opin Support Palliat Care 2013;7:183-91.

 

Coleman JJ, van der Sijs H, Haefeli WE, Slight SP, McDowell SE, Seidling HM, Eiermann B, Aarts J, Ammenwerth E, Slee A, Ferner RE. On the alert: future priorities for alerts in clinical decision support for computerized physician order entry identified from a European workshop. Opens external link in new window BMC Med Inform Decis Mak 2013;13:111.

 

Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration-effect relationship of  CYP3A inhibition by ritonavir in humans. Opens external link in new windowEur J Clin Pharmacol 2013; Jun 9, 2013;69:1795-800.

 

Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Opens external link in new windowEur J Clin Pharmacol 2013;69:507-13

 

Geist MJP, Egerer G, Burhenne J, Riedel K-D, Weiss J, Mikus G. Steady-state pharmacokinetics and metabolism of voriconazole in patients. Opens external link in new windowJ Antimicrob Chemother 2013;68:2592-9.

 

Grün B, Kiessling, MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE, Czock D. Trimpethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1. Opens external link in new windowBr J Clin Pharmacol 2013;76:787-96.

 

Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Opens external link in new windowPharmacogenomics J 2013;13:484-9.

 

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nonogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Opens external link in new windowClin Pharmacol Ther 2013;93:564-71.

 

Hof H, Mikus G. Candida-Infektionen im hohen Alter. Opens external link in new windowZ Gerontol Geriatr 2013;46:64-70.

 

Keller F, Hartmann B, Czock D. Time of effect duration and administration interval for sitagliptin in patients with kidney failure. Opens external link in new window Eur J Drug Metab Pharmacokinet 2014;39:77-85.

 

Klimas R, Witticke D, El Fallah S, Mikus G. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration. Opens external link in new windowExpert Opin Drug Metab Toxicol 2013;9:517-28.

 

Mahler C, Freund T, Baldauf A, Jank S, Ludt S, Peters-Klimm F, Haefeli WE, Szecsenyi J. Strukturiertes Medikamentenmanagement in der Hausarztpraxis - ein Beitrag zur Förderung der Arzneimitteltherapiesicherheit. Z Evid Fortbild Qual Gesundhwes 2013.

 

Markert C, Burhenne J, Weiss J, Mikus G, Haefeli WE. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Opens external link in new windowClin Pharmacol Ther 2014;95:250-1.

 

Markert C, Hellwig R, Burhenne J, Hoffmann MM, Weiss J, Mikus G, Haefeli WE. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Opens external link in new windowEur J Clin Pharmacol 2013;69:1785-93.

 

Müller O, Mockenhaupt FP, Marks B, Meissner P, Coulibaly B, Kuhnert R, Buchner H, Schirmer RH, Walter-Sack I, Sié A, Mansmann U. Haemolysis risk in methyleine blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Opens external link in new windowPharmacoepidemiol Drug Saf 2013;22:376-85.

 

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Akillu E, Burhenne J. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two Sub-Saharan Africa populations. Opens external link in new windowPlos One 2013;8:e67946.

 

Rigalli JP, Reuter T, Herold-Mende C, Dyckhoff G, Haefeli WE, Weiss J, Theile D. Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. Opens external link in new windowCancer Chemother Pharmacol 2013;1335-43.

 

Schiele JT, Quinzler R, Klimm H-D, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Opens external link in new windowEur J Clin Pharmacol 2013;69:937-48.

 

Seidling HM, Kaltschmidt J, Ammenwerth E, Haefeli WE. Medication safety through e-health technology: can we close the gaps?. Opens external link in new windowBr J Clin Pharmacol 2013;76 Suppl S1:i-iv.

 

Seidling HM, Lampert A, Lohmann K, Schiele JT, Send AFJ, Witticke D, Haefeli WE. Safeguarding the process of drug administration with an emphasis on electronic support tools. Opens external link in new windowBr J Clin Pharmacol 2013;76 Suppl 1:25-36.

 

Send A, Al-Ayyash A, Schecher S, Rudofsky G, Klein U, Schaier M, Pruszydlo MG, Witticke D, Lohmann K, Kaltschmidt J, Haefeli WE, Seidling HM. Development of a standardized knowledge base to generate individualized medication plans automatically with drug administration recommendations. Opens external link in new windowBr J Clin Pharmacol 2013;76 Suppl 1:37-46.

 

Skopp G, Mikus G. An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and its glucuronide. Opens external link in new windowAnal Bioanal Chem 2013;405:9449-53.

 

Stoll F, Burhenne J, Lausecker B, Weiss J, Thomsen T, Haefeli WE, Mikus G. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. Opens external link in new windowJ Clin Pharmacol 2013;53:1199-1204.

 

Theile D, Schmidt TT, Haefeli WE, Weiss J. In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. Opens external link in new window J Pharm Pharmacol 2013;65:1518-25.

 

Theile D, Spalwisz A, Weiss J. Watch out for reporter gene assays with renilla luciferase and paclitaxel.Opens external link in new window Anal Biochem 2013;15:109-10.

 

Theile D, Haefeli WE, Seitz HK, Millonig G, Weiss J, Mueller S. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Opens external link in new windowAlcohol Clin Exp Res 2013;37 Suppl 1:E17-22.

 

van Erp R, Czock D, Keller F. Pharmakotherapie bei Niereninsuffizienz – Fokus Chemotherapie, neue Antikoagulanzien, neue Antidiabetika. Klinikarzt 2013;42:518-523.

 

Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate expression and function of drug transporters and drug metabolising enzymes in vitro. Opens external link in new windowInt J Antimicrob Agents 2013;41:484-7.

 

Weiss J, Theile D, Rüppell MA, Speck T, Spalwisz A, Haefeli WE. Interaction profile of macitentan, a newnon-selective endothelin-1 receptor antagonist, in vitro. Opens external link in new windowEur J Pharmacol 2013;15:168-75.

 

Weiss J, Theile D, Spalwisz A, Burhenne J, Riedel K-D, Haefeli WE. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Opens external link in new windowBiochem Pharmacol13;85:265-73.

 

Witticke D, Seidling HM, Lohmann K, Send AFJ, Haefeli WE. Opportunities to reduce medication regimen complexity: A retrospective analysis of 500 patients discharged from a university hospital in Germany. Opens external link in new windowDrug Saf 2013;36:31-41.

 

Zembruski N, Nguyen C, Theile D, Ali R, Herzog M, Hofhaus G, Heintz U, Burhenne J, Haefeli WE, Weiss J. Liposomal sphingomyelin influences the cellular lipid profile of human lymphoblastic leukaemia cells without effect of P-glycoprotein activity. Opens external link in new windowMol Pharm 2013;10:1020-34.

 

Ziesenitz VC, König SK, Mahlke N, Jantos R, Skopp G, Weiß J, Haefeli WE, Mikus G. Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. Opens external link in new windowBasic Clin Pharmco Toxicol 2013;113:43-8.

 

Ziesenitz VC, van den Anker JN. Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl. Opens external link in new windowInt J Clin Pharmacol Ther 2013;51:991-2.

 

Ziesenitz VC, Weiss J, Haefeli WE, Mikus G. Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphisms. Opens external link in new windowClin Pharmacol Ther 2013;93:388.

 

 

Herausgebertätigkeit

Haefeli WE, Quinzler R, Seidling H, editors. Arzneimittel richtig anwenden. Stuttgart: Georg Thieme; 2013.

Publikationen 2012

Publikationen 2012

Ali R, Campos B, Dyckhoff G, Haefeli WE, Herold-Mende C, Burhenne J. Quantification of retinoid concentrations in human serum and brain tumor tissues. Anal Chim Acta 2012;725:57-66.

 

Baker U, Tomson G, Somé M, Kouyaté B, Williams J, Mpembeni R, Massawe S, Blank A, Gustafsson LL, Eriksen J. 'How to know what you need to do’: a cross-country comparison of maternal health guidelines in Burkina Faso, Ghana and Tanzania. Implement Sci 2012;7:31:1-13.

 

Bertsche T, Nachbar M, Fiederling J, Schmitt SPW, Kaltschmidt J, Seidling HM, Haefeli WE. Assessment of a computerised decision support system for allergic rhino-conjunctivitis counselling in German pharmacy. Int J Clin Pharm 2012;34:17-22

 

Billing H, Sommerer C, Giese T, Zeier M, Meuer S, Czock D, Tönshoff B. Increased cyclosporin A sensitivity in vivo in pediatric renal transplant recipients compared to adults. Ther Drug Monit 2012;34:554-60.

 

Burhenne J. Bioanalytical method validation. J Anal Bioanal Techniques 2012;3:e111. Editorial.

 

Burhenne J, Scope A. Evaluation of the influence of formulation, food intake, and species on voriconazole plasma concentration in birds. Vet Med Austria 2012;99:157-62.

 

Burhenne J, Halama B, Maurer M, Riedel K-D, Hohmann N, Mikus G, Haefeli WE. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem 2012;402:2439-50

 

Carow F, Rieger K, Walter-Sack I, Meyer MR, Peters FT, Maurer HH, Haefeli WE. Objective assessment of nonadherence and unknown co-medication in hospitalized patients. Eur J Clin Pharmacol 2012;68:1191-9.

 

Czock D, Keller F, Seidling H. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol 2012;74:66-74.  

 

Erler A, Beyer M, Petersen JJ, Saal K, Rath T, Rochon J, Haefeli WE, Gerlach FM. How to improve drug dosing for patients with renal impairment in primary care - a cluster-randomized controlled trial. BMC Fam Pract 2012;13:91.

 

Grün B, Merkel U, Riedel KD, Weiss J, Mikus G. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br J Clin Pharmacol 2012;74:854-63.

 

Haefeli WE. Polypharmazie: Therapien durchführbar machen und regelmäßig prüfen. Druckpunkt 2012;1:20-23.

 

Keubler A, Weiss J, Haefeli WE, Mikus G, Burhenne J. Drug interaction of efavirenz and midazolam: Efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. Drug Metab Dispos 2012;40:1178-82.

 

Kleber CJ, Spiess A, Kleber JB, Hinz U, Holland-Cunz S, Weiss J. Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. Eur J Pediatr 2012;171:941-6.

 

Mahler C, Hermann K, Janke S. Haefeli WE, Szecsenyi J. Can a feedback report and training on medication counseling for general practitioners improve patient satisfaction with information on medicines? Patient Prefer Adherence 2012;6:179-86.

 

Mahler C, Hermann K, Horne R, Jank S, Haefeli WE, Szecsenyi J. Patients' beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract 2012;18:409-13.

 

Maxwell S, Eichler H-G, Busics A, Haefeli WE, Gustafsson LL. e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. Br J Clin Pharmacol 2012;73:12-5

 

Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, Burhenne J, Lindquist L, Mugusi F, Sandstrom E, Eklillu E. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PloS One 2012;7:e40180.

 

Niethammer AG, Lubenau H, Mikus G, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winnenthal FH. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012;12:361.

 

Pruszydlo MG, Walk-Fritz SU, Hoppe-Tichy T, Kaltschmidt J, Haefeli WE. Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care. BMC Med Inform Decis Mak 2012;12:137.

 

Rigalli JP, Perdomo VG, Luquita MG, Villanueva SSM, Arias A, Theile D, Weiss J, Mottino AD, Ruiz ML, Catania VA. Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: Involvement of pregnane X-receptor. Plos Negl Trop Dis 2012;6:e1951.

 

Rother A, Glander P, Vitt E, Czock D, von Ahsen N, Armstrong VW, Oellerich M, Budde K, Feneberg R, Tönshoff B, Weber LT. Iosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. Eur J Clin Pharmacol 2012;68:913-22.

 

Theile D, Detering J-C, Herold-Mende C, Dyckhoff G, Haefeli WE. Weiss J, Burhenne J. Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry. J Pharmacol Exp Ther 2012;341:51-8.

 

Weiss J, Theile D, Haefeli WE. Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. Naunyn-Schmiedebergs Arch Pharmacol 2012;385:1025-34.

 

Weiss J, Fränkl SA, Flammer J, Grieshaber MC, Hollo G, Teuchner B, Haefeli WE. No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients. Mol Vis 2012;18:2174-81.

 

Witticke D, Seidling HM, Klimm HD, Haefeli WE. Do we prescribe what patients prefer? A pilot study to assess patients' preferences for medication regimen characteristics. Patient Prefer Adherence 2012;6:679-84.

 

Wustrow I, Riedel K-D, Mikus G, Weiss J. In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opiod metabolite nortilidine to bisnortilidine. Naunyn-Schmiedebergs Arch Pharmacol 2012;385:633-9.

 

Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli WE, Burhenne J, Aderaye G, Lindquist L, Aklillu E. High plasma efavirenz level and CYP2B*6 are associated with efavirenz-based HAART-induced liver injury in treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012;12:499-506.

 

Zembruski NCL, Stache V, Haefeli WE, Weiss J. 7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal Biochem 2012;429:79-81

 

 

Buchbeiträge

Konias M, Kaltschmidt J, Green K, Seidling HM, Haefeli WE. Entscheidungsunterstützung bei der medikamentösen Therapie älterer Patienten. In: Duesberg F, editor. e-Health 2012. Solingen: medical future verlag; 2012.

 

Blank A, Kaltschmidt J, Krings A,  Loukanova S,  Sauerborn R, Haefeli WE. e-Health in Afrika: Chancen eines Clinical Decision Support Systems in der medizinischen Grundversorgung im ländlichen Afrika. In: Duesberg F, editor. e-Health 2013. Solingen: medical future verlag; 2013.

 

 

Publikationen 2011

Publikationen 2011

 

Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, König S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol 2011;67:1139-45

 

Aly A-F, Menges K, Haas CH, Zimmermann L, Kaltschmidt J, Criegee-Rieck M. Voraussetzungen für elektronische Systeme zur Prüfung auf Arzneimitteltherapiesicherheit (AMTS). BGesBl 2011;54:1170-8.

 

Bertsche T, Mikus G. Unerwünschte Wirkungen und Wechselwirkungen in der Analgetikatherapie. Ther Umsch 2011;68:19-26.

 

Campos B, Centner F-S, Bermejo JL, Ali R, Dorsch K, Wan F, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A, Burhenne J, Herold-Mende C. Aberrant expression of retinoic acid signalling molecules influences patient survival in astrocytic gliomas. Am J Pathol 2011;178:1953-64.

 

Czock D, Keller F. Arzneimittelinteraktionen und Nephrotoxizität. Ther Umsch 2011;68:11-8.

 

Ding R, Frei E, Fardanesh M, Schrenk H-H, Kremer P, Haefeli WE. Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery. J Clin Pharmacol 2011;51:672-8

 

Eichbaum C, Haefeli WE. Nomenklaur und Einteilung von Biologicals. Ther Umsch 2011;68:593-601.

 

Fetzner L, Burhenne J, Weiss J, Völker M, Unger M, Mikus G, Haefeli WE. Daily honey consumption does not change CYP3A activity in humans. J Clin Pharmacol 2011;51:1223-32. 

 

Genovese S, Epifano F, Curini M, Menger D, Zembruski NCL, Weiss J. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression. Phytomedicine 2011;18:586-91.

 

Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli WE, Hoeper MM, Kähler CM, Haemmer H, Klose H, Köllner V, Kopp B, Mebus S, Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D, Voswinckel R, Olschewski H. Treatment of pulmonary arterial hypertension (PAH): Updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011;152S:S20-S33.

 

Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel K-D, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, Burhenne J, Aklillu E. Long-term effect of efavirenz autoinduction on plasma/PBMC drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotype among HIV patients. J Antimicrob Chemother 2011;66:2350-1.

  

Haefeli WE, Reinhart WH. Proteine als Therapeutika. Ther Umsch 2011;68:591.

 

Haefeli WE. Polypharmazie. Schweiz Med Forum 2011;11:847-52.

 

Haefeli WE, Quinzler R. Arzneimittelexposition bei älteren Patienten: modifizierende Faktoren und die Rolle von Gebrechlichkeit, Multimorbidität, psychosozialen Charakteristika und psychiatrischer Komorbidität. Z Gerontol Geriatr 2011;44(Suppl.2):36-7

  

Hafner-Blumenstiel V. Phytopharmaka als Ursache von unerwünschten Arzneimittelwirkungen. Ther Umsch 2011;68:54-7.

 

Hassan A, Burhenne J, Riedel K-D, Weiss J, Mikus G, Haefeli WE, Czock D. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 2011;33:86-93.

 

Herzog M, Storch CH, Gut P, Kotlyar D, Füllekrug J, Ehehalt R, Haefeli WE, Weiss J. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn-Schmiedebergs Arch Pharmacol 2011;383:1-11. 

 

Kaan HYK, Weiss J, Menger D, Ulaganathan V, Tkocz K, Laggner C, Popowycz F, Joseph B, Kozielski F. Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5. J Med Chem 2011;54:1576-86.

 

Katzenmaier S, Markert C, Riedel K-D, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011;90:666-73.

 

Kaufmann-Kolle P, Szecsenyi J, Broge B, Haefeli WE, Schneider A. Führt die Implementierung von offenem Benchmarking in datengestützten Qualitätszirkeln zur Verbesserung der hausärztlichen Versorgung bei Arzneimittelinteraktion und  Asthma bronchiale? Z Evid Fortbild Qual Gesundhwes 2011;105:389-95.

 

Kellner S, Seidu-Larry S, Burhenne J, Motorin Y, Helm M. A multifunctional bioconjugate module for versatile photoaffinity labeling and click chemistry of RNA. Nucleic Acids Res 2011;39:7348-60.

 

Mahler C, Jank S, Pruszydlo MG, Hermann K, Gärtner H, Kaltschmidt J, Ludt S, Bertsche T, Haefeli WE, Szecsenyi J. Heicare®: ein Projekt zur Verbesserung der sektorenübergreifenden Arzneimittelkommunikation. Dtsch Med Wochenschr 2011;136:2239-44.

 

Mikus G. Unerwünschte Arzneimittelwirkungen (UAW) und Arzneimittel-Interaktionen – Definition und Einteilung. Ther Umsch 2011;68:3-9.

 

Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011;12:861-72.

 

Motorin Y, Burhenne J, Teimer R, Koynov K, Willnow S, Weinhold E, Helm M. Expanding the chemical scope of RNA: methyltransferases to site-specific alkynylation of RNA for click labeling. Nucleic Acids Res 2011;39:1943-52.

 

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K-D, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WEH, Bertilsson L, Burhenne J, Aklillu E. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with and without tuberulosis. Clin Pharmacol Ther 2011;90:406-13.

 

Schmitt T, Mikus G, Egerer G. Leitliniengerechte Therapie von Übelkeit und Erbrechen. J Gastroenterol Hepatol Erkr 2011;9:18-24

 

Seidling HM, Phansalkar S, Seger DL, Paterno MD, Shaykevich S, Haefeli WE, Bates DW. Factors influencing alert acceptance: a novel approach for predicting success of clinical decision support. JAMIA 2011;18:479-84.

 

Senger C, Seidling HM, Quinzler R, Leser U, Haefeli WE. Design and evaluation of an ontology-based drug application database. Methods Inf Med 2011;50:273-84.

 

Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T. Pharmacogynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011;33:373-9.

 

Theile D, Ketabi-Kiyanvash N, Herold-Mende C, Dyckhoff G, Efferth T, Bertholet V, Haefeli WE, Weiss J. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head & Neck 2011;33:959-68. 

 

Volodina A, Bertsche T, Kostev K, Winkler V, Haefeli WE, Becher H. Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study. BMC Public Health 2011;11:509.

 

Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol 2011;660:298-304.

 

Weiss J, Haefeli WE. Interaction potential of the endothelin-A receptor antagonist atrasental with drug transporters and drug metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol 2011;68:1093-8.

 

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011;6:e27810.

 

Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011;4:198-206

 

Zachariah M, Phansalkar S, Seidling H, Neri PM, Cresswell KM, Duke J, Bloomrosen M, Volk LA, Btes DW. Development and validation of an instrument assessing implementation of human-factors principles medication-related decision-support systems - I-MeDeSa. J Am Med Inform Assoc 2011;18Suppl1:i62-72.

 

Zembruski NCL, Büchel G, Jödicke L, Herzog M, Haefeli WE, Weiss J. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 2011;66:802-12.

 

Zembruski NCL, Haefeli WE, Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother 2011;55:1282-4.

 

Publikationen 2010

Publikationen 2010

Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010;5:314-27. 

 

Bertsche T, Bertsche A, Krieg EM, Kunz N, Bergmann K, Hanke G, Hoppe-Tichy T, Ebinger F, Haefeli WE. Prospective pilot intervention study to prevent medication errors in drugs administered to children by mouth or gastric tube: A program for nurses, physicians and parents. Qual Saf Health Care 2010;19:e26.

 

Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, Walter-Sack I, Haefeli WE, Encke J. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 2010;36:665-72. 

 

Bertsche T, Veith C, Stahl A, Hoppe-Tichy T, Meyer FJ, Katus HA, Haefeli WE. A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities. Pharm World Sci 2010;32:663-9. 

 

Bertsche T, Pfaff J, Haefeli WE, Encke J. Interaktionsmanagement vermeidet Interaktionen. Pharm Ztg 2010;12:27-30.

 

Bountogo M, Zoungrana A, Coulibaly B, Klose C, Mansmann U, Mockenhaupt FP, Burhenne J, Mikus G, Walter-Sack I, Schirmer RH, Sié A, Meissner P, Müller O. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health 2010;15:713-7.

 

Burhenne J, Matthee AK, Pasakova I, Röder C, Heinrich T, Haefeli WE, Mikus G, Weiss J. No evidence for induction of ABC-transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 2010;54:4185-91.

 

Burkhardt O, Thon S, Burhenne J, Welte T, Kielstein JT. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents 2010;36:93-4.

 

Deppe S, Böger RH, Weiss J, Benndorf R. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010;6:863-71. 

 

Egerer G, Eisenlohr K, Gronkowski M, Riedel K-D, Burhenne J, Mikus G. The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010;70:903-7.

 

Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli WE, Held M, Hoeper MM, Kähler C-M, Kaemmerer H, Klose H, Köllner V, Kopp B, Mebus S, Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D, Voswinckel R, Olschewski H. Therapie der pulmonal arteriellen Hypertonie (PAH): Empfehlungen der Kölner Konsensus Konferenz 2010. Dtsch Med Wochenschr 2010;135:S87-101.

 

Hafner V, Czock D, Burhenne J, Riedel K-D, Bommer J, Mikus G, Machleidt C, Weinreich T, Haefeli WE. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodialfiltration. Antimicrob Agents Chemother 2010;54:2596-602.

 

Hafner V, Grün B, Markert C, Czock D, Mikus G, Haefeli WE. Arzneimittelinteraktionen. Internist 2010;51:359-70.

 

Hafner V, Haefeli WE. Simvastatin und Atorvastatin: Interaktionen mit CYP3A4 Hemmern. AVP 2010;37:15-6.

 

Hafner, V, Jäger M, Mattée A-K, Ding R, Burhenne J, Haefeli WE, Mikus G. Effect of simultaneous induction and inhibition of CYP3A by St. John's wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2010;87:191-6.

 

Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Ärztebl Int 2010;107:647-55.

 

Hassan A, Haefeli WE. Appropriateness of timing of drug administration in elctronic prescriptions. Pharm World Sci 2010;32:162-71.

 

Katzenmaier S, Markert C, Mikus G. Proposal of a new limited sampling strategy to predict CYP3A4 activity using a partial AUC of midazolam. Eur J Clin Pharmacol 2010;66:1137-41.

 

Kellner S, Burhenne J, Helm M. Detection of RNA modifications. RNA Biol 2010;7:237-47.

 

König S, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010;65:2319-28.

 

Mahler C, Hermann K, Horne R, Ludth S, Haefeli WE, Szecsenyi J, Jank S. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010;16:574-9. 

 

Maus S, Holch C, Czock D, Thalhammer F, Keller F, Hartmann B. Umfrage zur Arzneimitteldosierung bei Niereninsuffizienz unter nephrologisch tätigen Ärzten. Wien Klin Wochenschr 2010;122:479-85.

 

Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010;88:676-84.

 

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzmann D, Guenther S, Winnenburg R, Schroeder M, Preissner R. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010;38:D237-43.

 

Seidling HM, Paterno MD, Haefeli WE, Bates DW. Coded entry versus free-text and alert overrides: What you get depends on how you ask. Int J Med Inform 2010;79:792-6.

 

Seidling HM, Schmitt SPW, Bruckner T, Kaltschmidt J, Pruzydlo M, Senger C, Bertsche T, Walter-Sack I, Haefeli WE. Patient-specific electronic decision support reduces prescription of excessive doses. Qual Saf Health Care 2010;19:e15. 

 

Senger C, Kaltschmidt J, Schmitt SPW, Pruszydlo MG, Haefeli WE. Misspellings in drug information system queries: Characteristics of drug name spelling errors and straegies for their prevention. Int J Med Inform 2010;79:832-9.

 

Sertel S, Eichhorn T, Sieber S, Sauer A, Weiss J, Plinkert PK, Efferth T. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem-Biol Interact 2010;185:42-52.

 

Sommerer C, Müller-Krebs S, Schaier M, Glander P, Budde K, Schwenger V, Mikus G, Zeier M. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010; 69:346-57.

  

Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-74.

 

Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010;66:291-8.

 

Theile D, Staffen B, Weiss J. ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem 2010;399:246-50. 

 

Weiss J, Haefeli WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol 2010;280:219-79.

 

Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Böger RH, Haefeli WE, Benndorf RA. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010;31:150-61.

 

Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Stürmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010;19:1248-55.  

 

Buchbeiträge 

 

Bertsche T, Kaltschmidt J, Bardenheuer HJ, Haefeli WE. Verbesserte Schmerzbehandlung bei Tumorpatienten durch elektronische Unterstützung. In: Duesberg F, editor. e-Health 2010. Solingen: POINT63 Media- und Verlagsservice; 2010.

 

Haefeli WE. Therapie-Monitoring, Probleme der Compliance (Adherence) und Noncompliance. In: Lemmer B, Brune K, editors. Pharmakotherapie. Klinische Pharmakologie. 14th ed. Heidelberg: Springer; 2010.

 

Stracke S, Czock D. Systematik des Nierenversagens. In: Hautmann R, editor. Urologie. 4th ed. Heidelberg: Springer Medizin Verlag; 2010.

Publikationen 2009

Publikationen 2009

Benkhaial A, Kaltschmidt J, Weisshaar E, Diepgen TL, Haefeli WE. Prescribing errors in patients with documented drug allergies: Comparison of ICD-10 coding and written patient notes. Pharm World Sci 2009;31:464-72.

 

Bertsche T, Askoxylakis V, Habl G, Laidig F, Kaltschmidt J, Schmitt SPW, Ghaderi H, Zabel-du Bois A, Milker-Zabel S, Debus J, Bardenheuer HJ, Haefeli WE. Multidisciplinary pain management based on computerized clinical decision support system in cancer pain patients. Pain 2009;147:20-8.

 

Bertsche T, Kaltschmidt J, Haefeli WE. Patientensicherheit durch computerbasierte Arzneimittelinformation - Der Patient im elektronischen Check-up. Internist 2009;50:748-56.

 

Bertsche T, Münk L, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J, Haefeli WE. One-year follow-up on procedure to prevent i.v. drug incompatabilities in an intensive care unit. Am J Health Sys Pharm 2009;66:1250,1253.

 

Bertsche T, Fleischer M, Pfaff J, Encke J, Czock D, Haefeli WE. Pro-active provision of drug information as a technique to address overdosing in intensive care patients with renal insufficiency. Eur J Clin Pharmacol 2009;65:823-9.

 

Bertsche T, Schulz M, Schubert-Zsilavecz M. Klinische Pharmazeuten verbessern die Sicherheit der Arzneimitteltherapie. Dt Apoth Ztg 2009;149:3032-3.

 

Bertsche T, Schwalbe O, Högger P. Klinische Pharmazie: Eine Bestandsaufnahme an deutschen Universitäten. Pharm Ztg 2009;48:154:60-4.

 

Blank A, Hellstern V, Schuster D, Hartmann M, Matthée A-K, Burhenne J, Haefeli WE, Mikus G. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 2009;48:1787-9.

  

Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 2009;50:143-54.

  

Czock D, Bertsche T, Haefeli WE. Drug dose adjustment in patients with renal impairment. Am J Kidn Dis 2009;54:983-4. (letter)

 

Czock D, Keller F, Hameister J, Tiefenbach B, Mitzner S. Levomethadone is poorly removed by the molecular adsorbents recirculating system. J Clin Psychopharm 2009;29:622-4. (letter)

 

Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol 2009;5:475-87.

 

Czock D, Rasche FM, Boesler B, Shipkova M, Keller F. Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 2009;43:363-9.

 

Grün B, Haefeli WE. Die richtige Rekrutierung von Studienteilnehmern. Bundesgesundheitsbl 2009;52:402-9.

 

Grün B, Krautter S, Riedel K-D, Mikus G. Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole. Br J Clin Pharmacol 2009;68:712-20.

 

Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE. The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci 2009;31:426-31. 

 

Keller F, Hartmann B, Czock D. Mean residence time as estimated from cropped and truncated moments. Arzneimittelforschung 2009;59:377-81.

 

Keller F, Hartmann B, Czock D. Explicit solution of integrated 1 - exp equation for predicting accumulation and decline of concentrations for drugs obeying nonlinear saturation kinetics. Ther Drug Monit 2009;31:783-5.

  

Kremer P, Mahmoudreza F, Ding R, Pritsch M, Zoubaa S, Frei E. Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery 2009;63(Suppl 3):53-61.

 

Mahler C, Jank S, Hermann K, Haefeli WE, Szecsenyi J. Informationen zur Medikation - wie bewerten chronisch kranke Patienten das Medikamentengespräch in der Arztpraxis? Dtsch Med Wochenschr 2009; 134:1620-4.

 

Mahler C, Jank S, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J. Psychometric properties of a German version of the "Satisfaction with Information about Medicine Scale" (SIMS-D). Value Health 2009;12:1176-9. 

 

Peters FT, Drvarov O, Lottner S, Spellmeier A, Rieger K, Haefeli WE, Maurer HH. A systematic comparison of four different workup procedures for systematic toxicological analysis of urine samples using gas chromatography-mass spectrometry. Anal Bioanal Chem 2009;393:735-45.

 

Quinzler R, Schmitt SP, Pritsch M, Kaltschmidt J, Haefeli W. Substantial reduction of inappropriate tablet splitting with computerised decision support: a prospective intervention study assessing potential benefit and harm. BMC Med Inform Decis Mak 2009;9:30.

 

Reimer K, Hopp M, Zenz M, Maier C, Holzer P, Mikus G, Bosse B, Smith K, Buschmann-Kramm C, Leyendecker P. Meeting the challenge of opioid-induced constipation in chronic pain management - A novel approach. Pharmacology 2009;83:10-7.

 

Schless B, Yildirim S, Beha D, Keller F, Czock D. Rituximab in two casses of Goodpasture's syndrome. NDT plus 2009;2:225-7.

 

Scholz I, Oberwittler H, Riedel K-D, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15.

  

Schwalbe O, Keiner D, Bertsche T. Der geriatrische Patient. Dt Apoth Ztg 2009;149:5748-9.

 

Seidling HM, Storch CH, Bertsche T, Senger C, Kaltschmidt J, Walter-Sack I, Haefeli WE. Successful strategy to improve the specificity of electronic statin-drug interation alerts. Eur J Clin Pharmacol 2009;65:1149-57. 

 

Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009;78:1366-73.

 

Walk SU, Fritz S, Pruszydlo MG, Hartwig W, Haefeli WE, Hoppe-Tichy T. Pharmazeutische Beratung zu Medikationsumstellungen an der Schnittstelle von ambulanter zu stationärer Versorgung. Krankenhauspharmazie 2009;30:218-21.

 

Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, Meissner P, Mikus G. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 2009;65:179-89.

 

Warth A, Goeppert B, Bopp C, Schirmacher P, Flechtenmacher C, Burhenne J. Turquoise to dark green organs at autopsy. Virchows Arch 2009;454:341-4.

 

Weiss J, ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;49:196-204.

 

Weiss J, Herzog, Koenig S, Storch CH, Ketabi-Kiyanvash N, Haefeli WE. Induction of multiple drug transporters by efavirenz. J Clin Pharmacol Sci 2009;109:242-50.

 

Weiss J, Sauer A, Herzog M, Böger RH, Haefeli WE, Benndorf RA. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 2009;84:264-70.

 

Buchbeiträge

Czock D, Aymanns C. Pharmakokinetik und Dosisanpassung bei Patienten mit Niereninsuffizienz. In: Keller F, Ketteler M, Schindler R, Heemann U, Wolf G, editors. Manuale nephrologicum. 2nd ed. München-Orlando: Dustri Verlag Dr. Karl Feistle; 2009.

 

 

Publikationen 2008

Publikationen 2008

Bertsche T, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J, Haefeli WE. Prevention of intravenous drug incompatabilities in an intensive care unit. Am J Health Syst Pharm 2008;65:1834-40.

 

Bertsche T, Hoppe-Tichy T, Haefeli WE. Arzneimittelbezogene Probleme erkennen und lösen - Wechselwirkung  zwischen Digoxin und Clarithromycin. Cosmas 2008;1:22-4.

 

Bertsche T, Niemann D, Mayer Y, Ingram K, Hoppe-Tichy T, Haefeli WE. Prioritising the prevention of medication handling errors. Pharm World Sci 2008;30:907-15. 

  

Bertsche T, Walk SU, Pruszydlo MG, Kaltschmidt J, Hoppe-Tichy T, Haefeli WE. Arzneimitteltherapie an intersektoralen Schnittstellen - Lösungsstrategien zur Qualitätssicherung. Krankenhauspharmazie 2008;29:163-6.

 

Burhenne J, Haefeli WE, Hess M, Scope A. Pharmacokinetics, tissue concentratons, and safety of the antifungal voriconazole in chickens. J Avian Med Surg 2008;22:199-207.

 

Burhenne J, Riedel K-D, Rengelshausen J, Meissner P, Müller O, Mikus G, Haefeli WE, Walter-Sack I. Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. J Chromatogr B 2008;863:273-82.

 

Czock D, Keller F, Paar WD, Thalhammer F. Nierenersatztherapie beim kritisch Kranken. Soll man Antibiotika bei kontinuierlicher Hämofiltration anders dosieren? Intensiv- und Notfallbehandlung 2008;33:169-83.

 

Gut F, Schiek W, Haefeli WE, Walter-Sack I, Burhenne J. Cation exchange resins as pharmaceutical carriers fo rmethylene blue: Binding and release. Eur J Pharm Biopharm 2008;69:582-7.

 

Haefeli WE. Erwiderung zu: Medizinische Probleme und Risiken bei der rabattvertragsrechtlichen Umstellung von Inhalatoren in Deutschland. Dtsch Med Wochenschr 2008;133:1857-8. (letter)

 

Haefeli WE, Walter-Sack I. Dosierungsbesonderheiten am Anfang und Ende einer Therapie. Ther Umsch 2008;65:573-5.

 

Hafner V, Albermann N, Haefeli WE, Ebinger F. Inhibition of voriconazole metabolism by chlorampehnicol in an adolescent with central nervous system aspergillosis. Antimibrob Agents Chemother 2008;52:4172-4.

 

Hafner V, Rutsch C, Ding R, Heinrich T, Diedrichs L, Schmidt-Gayk H, Walter-Sack I, Bommer J, Mikus G. Calcium balance during calcitriol and paracalcitol administration in healthy humans. Int J Clin Pharmacol Ther 2008;46:131-5.

 

Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss J. Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008;64:555-63.

 

Harenberg J, Weiss C, Mikus G, Jörg I, Vukojevic Y. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008;6:890-2.

 

Heinrich T, Heidt H, Hafner V, Schmidt-Gayk H, Jenetky E, Walter-Sack I, Mikus G, Bommer J. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant 2008;23:2861-7.

 

Hilbel T, Helms TM, Mikus G,  Katus HA, Zugck C. Telemetrie - Szenarien im klinischen Umfeld. Herzschr Elektrophys 2008;19:146-54.

 

Jank S, Bertsche T, Herzog W, Haefeli WE. Patient knowledge on oral anticoagulants: results of a questionnaire survey in Germany and comparison with the literature. Int J Clin Pharmacol Ther 2008;46:280-8.

 

Kaltschmidt J, Schmitt SPW, Pruszydlo MG, Haefeli WE. Characteristis of effective electronic mail messages distributed to healthcare professionals in a hospital setting. JAMIA 2008;15:235-9.

 

Meissner PE, Mandi G, Mockenhaupt FP, Witte S, Coulibaly B, Mansmann U, Frey C, Merkle H, Burhenne J, Walter-Sack I, Müller O. Marked differences in the prevalence of chloroquine resistance between urban and rural communities in Burkika Faso. Acta Trop 2008;105:81-6.

 

Pfeiffer K, Some F, Müller O, Sie A, Kouyaté B, Haefeli WE, Zoungrana A, Gustafsson LL, Tomson G, Sauerborn R. Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso. Trop Med Int Health 2008;13:418-26.

 

Pruszydlo MG, Quinzler R, Kaltschmidt J, Haefeli WE. Medizinische Probleme und Risiken bei der rabattvertragsgerechten Umstellung von Medikationen in Deutschland. Dtsch Med Wochenschr 2008;133:1423-8.

 

Quinzler R, Bertsche T, Szecsenyi J, Haefeli WE. Teilung von Tabletten: welchen Einfluss haben die Rabattverträge auf die Verordnungsqualität? Med Klin 2008;103:569-74.

 

Rittner C, Taupitz J, Walter-Sack I, Wessler I. Die neuen Musterbedingungen für die Probandenversicherung als Pflichtversicherung (AVB-Prob/AMG-JV) und für die nicht der Versicherungspflicht unterliegende klinische Prüfung (AVB-Prob/NV-Objekt) - ein Fortschritt für die Versicherten. VersR 2008;4:18-63.

 

Schneider A, Wensing M, Biessecker K, Quinzler R, Kaufmann-Kolle P, Szecsenyi J. Impact of quality cirlces for improvement of asthma care: results of a randomized controlled trial. J Eva. Clin Pract 2008;14:185-90.

 

Steiner T, Walter-Sack I, Taupitz J, Hacke W, Strowitzki T. Ethische und juristische Aspekte beim Einschluss nicht einwilligungsfähiger Patienten in Akuttherapie-Studien. Dtsch Med Wschr 2008;133:787-92.

 

Storch CH, Nikendei C, Schild S, Haefeli WE, Weiss J, Herzog W. Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls. Int J Eat Disord 2008;41:432-8.

 

Walk SU, Bertsche T, Kaltschmidt J, Pruszydlo MG, Hoppe-Tichy T, Walter-Sack I, Haefeli WE. Rule-based standardised switching of drugs at the interface between primary and tertiary care. Eur J Clin Pharmacol 2008;64:319-27.

 

Weiss J, Sawa E, Riedel K-D, Haefeli WE, Mikus G. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn-Schmiedebergs Arch Pharmacol 2008;378:275-82.

 

Weiss J, Weis N, Ketabi-Kiyanvash N, Storch CH, Haefeli WE. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 2008;579:104-9.

 

Zoungrana A, Coulibaly B, Sié A, Walter-Sack I, Mockenhaupt FP, Kouyaté B, Schirmer H, Klose C, Mansmann U, Meissner P, Müller O. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: A randomized controlled trial from Burkina Faso. PLoS ONE 2008;3, Epub e1630, Feb. 20.

 

 

Buchbeiträge

 

Haefeli WE. Arzneimittelverabreichung in der Notfallmedizin. In: Schoenenberger RA, Haefeli WE, Schifferli J, editors. Internistische Notfälle. 8th ed. Stuttgart New York: Georg Thieme; 2008.

 

Haefeli WE. Pharmakaverzeichnis. In: Schoenenberger RA, Haefeli WE, Schifferli J, editors. Internistische Notfälle. 8th ed. Stuttgart New York: Georg Thieme; 2008.

 

Kaltschmidt J, Haefeli WE. Essenzielle Charakteristika eines Arzneimittel-Informationssystems am Beispiel der Eigentwicklung AiDKlinik des Universitätsklinikums Heidelberg. In: Jäckel A, editor. Telemedizinführer Deutschland. 8th ed. Bad Nauheim; 2008.

 

 

Herausgebertätigkeit

 

Schoenenberger RA, Haefeli WE, Schifferli J, editors. Internistische Notfälle. 8th ed. Stuttgart New York: Georg Thieme; 2008.

 

 

 

 

Publikationen 2007

Publikationen 2007

Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M. Renal safety and pharmacokineticsof ibandronate in multiple myeloma patients with our without impaired renal function. J Clin Pharmacol 2007;47:942-50.

 

Bertsche T, Haemmerlein A, Schulz M. German national drug information service: user satisfaction and potential positive patient outcomes. Pharm World Sci 2007;29:167-72.

 

Derendorf H, Huebner M, Drewelow B, Fuhr U, Gleiter C, Lemmer B, Mikus G, Roots I, Ziegler A, Ukena D. Ciclesonid - Pharmakokinetische und pharmakodynamische Eigenschaften. Arzneimitteltherapie 2007;25:89-94.

 

Dietz L, Glaz-Sandberg A, Nguyen H, Skopp G, Mikus G, Aderjan R. The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther Drug Monit 2007;29:368-72.

 

Ehrhardt M, Möck M, Haefeli WE, Mikus G, Burhenne J. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. J Chromatogr B 2007;850:249-258.

 

Gehrig AK, Mikus G, Haefeli WE, Burhenne J. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plaslma. Rapid Commun Mass Spectrom 2007;21:2704-16.

 

Geist MJP, Egerer G, Burhenne J, Riedel K-D, Mikus G. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia - importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007;51:3455-6.

 

Glaz-Sandberg A, Dietz L, Nguyen H, Oberwittler H, Aderjan R, Mikus G. Pharmacokinetics of 11-nor-carboxy-delta-9-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther 2007;82:63-9.

 

Haefeli WE. Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease. J Neurol 2007;254(Suppl 4):IV/29-36.

 

Haefeli WE. Riskante Teilung. Pharm. Ztg. 2007;152(3):178.

 

Indermitte J, Erba L, Beutler M, Bruppacher R, Haefeli WE, Hersberger KE. Managment of potential drug interactions in community pharmacies: A questionnaire-based survey in Switzerland. Eur J Clin Pharmacol 2007;63:297-305.

 

Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, Haefeli WE, Bertilsson L. CYP3A5 genotypes has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007;81:708-12.

 

Kaltschmidt J, Haefeli WE. Mittel zum Zweck. Special IT-Systeme. Krankenhaus - Technik + Management, Okt. 2007, S.38-41.

 

Ketabi-Kiyanvash N, Herold-Mende C, Kashfi F, Caldeira S, Tommasino M, Haefeli WE, Weiss J. NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. Cell Tissue Res 2007;328:19-29.

 

Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr K-H, Ding R, Haefeli WE, Mikus G. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 2007;47:70-7.

 

Quinzler R, Schmitt SPW, Szecsenyi J, Haefeli WE. Optimizing informatíon on drug exposure by collection of package code information in questionnaire surveys. Pharmacoepidemiol Drug Saf 2007;16:1024-30.

 

Quinzler R, Szecsenyi J, Haefeli WE. Tablet splitting: patients and physicians need better support. (letter) Eur J Clin Pharmacol 2007;63:1203-4.

  

Rengelshausen J, Goeggelmann C, Burhenne J, Riedel K-D, Mikus G, Walter-Sack I, Haefeli WE.  Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. Int J Clin Pharmacol Ther 2007;45:431-7.

 

Roeder C, Heinrich T, Gehrig A-K, Mikus G. Misleading results of screening for illicit drugs during efavirenz treatment. AIDS 2007;21:1390-1.

 

Schneider A, Wensing M, Quinzler R, Bieber Ch, Szecsenyi J. Higher preference for participation in treatment decisions is associated with lower medication adherence in asthma patients. Patient Educ Couns 2007;67:57-62.

 

Schneider A, Biessecker K, Quinzler R, Kaufmann-Kolle P, Meyer FJ, Wensing M, Szecsenyi J. Asthma patients with low perceived burden of illness: a challange for guideline adherence. J Eval Clin Pract 2007;13:846-52.

  

Seidling HM, Al Barmawi A, Kaltschmidt J, Bertsche T, Pruszydlo MG, Haefeli WE. Detection and prevention of prescriptions with excessive doses in electronic prescribing systems. Eur J Clin Pharmacol 2007;63:1185-92.

 

Stiefel M, Reiss T, Staege M, Rengelshausen J, Burhenne W, Wawer A, Foell JL. Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. Pediatr Blood Cancer 2007;49:203-7.

 

Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73:1573-81.

 

Storch CH, Klimm H-D, Heinrich T, Haefeli WE, Weiss J. Plasma LDL cholesterol has no impact on p-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn-Schmiedeberg's Arch Pharmacol 2007;376:135.43.

 

Storch CH, Ehehalt R, Haefeli WE, Weiss J. Localisation of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007;323:257-64.

 

Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicerob Agents Chemother 2007;51:239-44.

 

Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007;59:238-45.

 

Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007;35:340-4.

 

 

Buchbeiträge

Haefeli WE, Klotz U. Interindividuelle Variabilität der Arzneimittelwirkung. In: Estler CJ, Schmidt H, editors. Pharmakologie und Toxikologie. 6th ed. Stuttgart New York: Schattauer; 2007.

 

Haefeli WE. Therapie-Monitoring, Probleme der Compliance (Adherence) and Noncompliance. In: Lemmer B, Brune K, editors. Pharmakotherapie. Klinische Pharmakologie. 13th ed. Heidelberg: Springer Medizin Verlag; 2007.

 

Walter-Sack I, Bertsche T. Immunsuppressive Arzneimittel - mögliche Wechselwirkungen. In: Beimler J, Schmidt J, Büchler M, Zeier M, Herausgeber. Heidelberger Manual der Nieren- und Pankreastransplantation, 2. Aufl. Universitätsklinikum Heidelberg, Abteilung für Allgemeine, Viszerale- und Transplantationschirurgie, Nierenzentrum Heidelberg, Sektion Nephrologie, Medizinische Universitätsklinik Heidelberg; 2007.

Publikationen 2006

Publikationen 2006

Bergner R, Hoffmann M, Riedel KD, Mikus G, Heinrich DM, Haefeli WE, Uppenkamp M, Walter-Sack I. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg independent of filtration rate. Nephrol Dial Transplant 2006;21:1019-23.

 

Bertsche T, Bardenheuer HJ. Arzneimittelanwendung in der Therapie chronischer Schmerzen. Ther Umsch 2006;63:391-7.

 

Bertsche T, Ghaderi H, Bardenheuer HJ, Haefeli WE. Schmerzpflaster - Reden vor dem Kleben. Pharm Ztg 2006;151:1878-84.

 

Bertsche T, Haas M, Oberwittler H, Haefeli WE, Walter-Sack I. Arzneimittel in Schwangerschaft und Stillzeit. Neue Risikofaktoren - dargestellt am Beispiel von Antibiotika. Dtsch Med Wochenschr 2006;131:1016-22.

 

Bertsche T, Haefeli WE. Maßgeschneiderte Arzneimitteltherapie bei Niereninsuffizienz. CHAZ 2006;7:77-82.

 

Bertsche T, Haefeli WE. Maßgeschneiderte Arzneimitteltherapie bei Interaktionen. CHAZ 2006;7:281-6.

 

Bertsche T, Haefeli WE. Klinische Pharmazie: Individualisierte Arzneimitteltherapie bei Patienten mit Niereninsuffizienz. Pharm Ztg 2006;151:717-23.

 

Bertsche T, Kaltschmidt J, Haefeli WE. Elektronische Arzneimittelinformationsmedien - Chancen (v)erkannt? Dtsch Arztebl 2006;103:A1438-42.

 

Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivistö KT. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol 2006;62:613-9.

 

Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schroder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fatkenheuer G, Cornely OA. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2006;28:262-5.

 

Geist M, Egerer G, Burhenne J, Mikus G. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother 2006;50:3227-8.

 

Haefeli WE. Verabreichungsfehler - welche Informationen braucht ein Patient, um seine Arzneimittel-Therapie sicher durchzuführen? Ther Umsch 2006;63:363-5.

 

Haefeli WE. Individualisierung der Evidenz: Single Case Randomized Trial. Ther Umsch 2006;63:777-81.

 

Hartge F, Wetter T. Haefeli WE. A similarity measure for case based reasoning modeling with temporal abstraction based on cross-correlation. Comput Meth Prog Bio 2006;81:41-8.

 

Hesse C, Luntz SP, Siedler H, Unnebrink K, Mikus G, de Bruijn M, Zondag E, de Vries M, Seibert-Grafe M, Haefeli WE. Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. Br J Clin Pharmacol 2006;61:414-9.

 

Kees F, Bucher M, Schweda F, Gschaidmeier H, Burhenne J, Mikus J. Comparative bioavailability of the microemulsion formulation of cyclosporine (neoral) with a generic dispersion formulation (cicloral) in young healthy volunteers. Ther Drug Monit 2006;28:312-20.

 

Knaup P, Pilz J, Kaltschmidt J, Ludt S, Szecsenyi J, Haefeli WE. Standardized documentaion of drug recommendations in discharge letters: A contribution to quality management in cooperative care. Methods Inf Med 2006;45:336-42.

 

Mach von MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006;6. Epub Sept. 2006.

 

Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer HR, Kouyate B, Mueller O. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malaria J 2006;5: Epub Oct. 2006.

 

Mikus G, Schöwel V, Drzewinska M. Rengelshausen J, Ding R, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Haefeli WE: Potent CYP2C19 genotype related interaction between voriconazole and the CYP3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35.

 

Möller M, Weiss J, Wink M. Reduction of cytotoxicity of the alkaloid emetine through P-glycoprotein (MDR1/ABCB1) in human Caco-2 cells and leukemia cell lines. Planta Med 2006;12:1121-6.

 

Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006;60:707-15. 

 

Peters T, Lindenmaier H, Haefeli WE, Weiss J. Interaction of th mitotic kinesin Eg5 inhibitor monastrol with p-glycoprotein. Naunyn-Schmiederberg's Arch Pharmacol 2006;372:291-9.

 

Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 2006;62:1065-73.

 

Quinzler R, Haefeli WE. Tabletten teilen. Ther Umsch2006;63:441-7.

 

Rengelshausen J, Beedgen B, Tsamouranis K, Mikus G, Walter-Sack I, Haefeli WE, Linderkamp O. Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age. Eur J Clin Pharmacol 2006;62:773-7.

 

Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2-values. Drug Metab Dispos 2006;34:203-7.

 

 

 

 

Publikationen 2005

Publikationen 2005

Akoachere M, Buchholz K, Fischer E, Burhenne J, Haefeli WE, Schirmer H, Becker K. In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother 2005;49:4592-7.

 

Albermann N, Schmitz-Winnenthal FH, Z'graggen K. Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005;70:949-58.

 

Berger MM, Hesse C, Dehnert C, Siedler H, Kleinbongard P, Bardenheuer HJ, Kelm M, Bärtsch P, Haefeli WE. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am J Respir Crit Care Med 2005;172:763-7.

 

Bergk V, Gasse C, Schnell R, Haefeli WE. Mail surveys - Obsolescent model or valuable instrument in general practice research? Swiss Med Wkly 2005;135:189-91.

 

Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence deom the literature. Eur J Clin Pharmacol 2005;61:327-35.

 

Bertsche T, Haefeli WE. Klinisch-pharmazeutische Kurzbewertung: Schlafmedikation auf den Patienten abstimmen. Pharm Ztg 2005;150:1700-4.

 

Bertsche T, Haefeli WE. Klinisch-pharmazeutische Kurzbewertung: Mögliche Interaktionen identifizieren. Pharm Ztg 2005;150:3552-5.

 

Bertsche T, Fritz R, Sauer P. Encke J. Haefeli WE, Walter-Sack I. Off-Label-Use in der Langzeitantikoagulation nach Lebertransplantation wegen phenprocoumoninduzierten Leberversagens. Med Klin 2005;100:820-4.

 

Borwitzky H, Haefeli WE, Burhenne J. Analysis of methylene blue in human urine by capillary electrophoresis. J Chromatogr B 2005;826:244-51.

 

Eckhardt M, Bertsche T, Schulz M, Jaehde U. Seamless Care in der Pharmazie - 1. Entwicklung und internationaler Vergleich. Med Monatsschr Pharm 2005;28:150-7.

 

Eckhardt M, Reinecke MF, Bertsche T, Schulz M, Jaehde U. Seamless care in der Pharmazie - 2. Befragung von Apothekern und Patienten in Deutschland. Med Monatsschr Pharm 2005;28:315-20.

 

Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94-537-43.

 

Groebner W, Walter-Sack I. Therapie der Hyperurikämie und Gicht. Med Monatsschr Pharm 2005;28:159-64.

 

Hesse C, Siedler H, Burhenne J, Riedel K-D, Haefeli WE. Fluvoxamine affects sildenafil kinetics and dynamics. J Clin Psychopharmacol 2005;25:589-92.

 

Hesse C, Siedler H, Luntz SP, Arendt BM, Goerlich R, Fricker R, Heer M, Haefeli WE. Modulation of endothelial and smooth muscle function by bed rest and hypoenergetic, low-fat nutrition. J Appl Physiol 2005;99-2196-203.

 

Lindenmaier H, Becker M, Haefeli WE, Weiss J. Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos 2005;33:1576-9.

 

Mandi G, Witte S, Meissner P, Boubacar C, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Wuest K, Walter-Sack I, Mikus G, Burhenne J, Riedel K-D, Schirmer H, Kouyate B, Mueller O. Safetey of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health 2005;10:32-8.

 

Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, Bergk V, Haefeli WE. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 2005;60:807-11.

 

Meissner P, Mandi G, Witte S, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Tapsoba T, Walter-Sack I, Mikus G, Burhenne J, Riedel K-D, Schirmer H, Kouyaté B, Mueller O. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso. Malar J 2005;4:45.

 

Mikus G, Weiss J. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Current Pharmacogenomics 2005;3:43-52.

 

Nikendei C, Zipfel S, Kraus B, Friedrich HC, Faber R, Löwe B, Müller-Tasch T, Schwab M, Mikus G, Bobbert M, Herzog W, Jünger J. Integrierte Psychosomatik: Implementierung und Evaluation eines Unterrichtsmoduls für StudentInnen der Inneren Medizin. GMS Z Med Ausbildung 2005; 22:Doc 213.

 

Parlar H, Burhenne J, Coelhan M, Vetter W. Structure of the toxaphene compound 2,5-endo, 6-exo, 8, 9, 9, 10, 10-octachlorobornene-2: A temperature-dependent formation of two rotamers. Environ Sci Technol 2005;39:1736-40.

 

Rengelshausen J, Banfield M, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78:25-33.

 

Streit M, Goeggelmann C, Dehnert C, Burhenne J, Riedel K-D, Menold E, Mikus G, Bärtsch P, Haefeli WE. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4500 meters). Eur J Clin Pharmacol 2005;61:39-46.

 

Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. FORST (kava-kava) inhibit p-glycoprotein in vitro. Drug Metab Dispos 2005;33:1580-3.

Publikationen 2004

Publikationen 2004

Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole induced QT interval prolongation and ventricular tachycardia. A non-concentration dependent adverse effect. Clin Infect Dis 2004;39:e50-2.

 

Bähring S, Rauch A, Toka O, Schroeder Ch, Hesse Ch, Siedler H, Fesüs G, Haefeli WE, Busjahn A, Aydin A, Neuenfeld Y, Mühl A, Toka HR, Gollasch M, Jordan J, Luft FC. Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension 2004;43[part2]:671-6.

 

Bergk V, Gasse C, Schnell R, Haefeli WE. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 2004;60:595-602.

 

Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: Impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004;76:85-96.

 

Ding R, Tayrouz Y, Riedel K-D, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76:73-84.

 

Döring A, Fröhlich M, Löwel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004;172:281-6.

 

Ehrhardt M, Lindenmaier H, Burhenne J, Haefeli WE, Weiss J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 2004;67:285-92.

 

Fricker R, Hesse C, Weiss J, Tayrouz Y, Hoffmann MM, Unnebrink K, Mansmann U, Haefeli WE. Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol 2004;58:169-77.

 

Friederich HC, Michaelsen J, Hesse C, Schellberg D, Schwab M. Herzog W. Treatment of recurrent cardioinhibitory neurocardiogenic syncope with Ipratropiumbromide. Z Kardiol 2004;93:479-85.

 

Fröhlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004;68:2409-16.

 

Fröhlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE. Assocation of CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. (letter) Br J Clin Pharmacol 2004;58:443-4.

 

Fröhlich M, Burhenne J, Martin-Facklam M, Weiss J, von Wolff M, Strowitzki T, Walter-Sack I, Haefeli WE. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004;57:244-52.

 

Hauser ER, Crossman DC, Granger CG, Haines JL, Johnes CJ, Mooser V, McAdam B, Winkelmann BR, Wiseman AH, Muhlestein JB, Bartel AG, Dennis CA, Dowdy E, Estabrooks S, Eggleston K, Francis S, Roche K, Clevenger PW, Huang L, Pedersen B, Shah S, Schmidt S, Haynes C, West S, Asper D, Booze M, Sharma S, Sundseth S, Middleton K, Roses AD, Hauser MA, Vance JM, MA Pericak-Vance, Kraus WE. A genomewide scan for early-onset coronary artery disease in 438 families: The GENECARD study. Am J Hum Genet 2004;75:436-47.

 

März W, Boehm BO, Winkelmann BR, Hoffmann MM. The P1A1/A2 polymorphism of platelet glycoprotein IIIa is not associated with the risk of type 2 diabetes. The Ludwigshafen risk and cardiovascular health study. Diabetologia 2004;47:1969-73.

 

März W, Nauck M, Hoffmann MM, Nagel D, Boehm BO, Koenig W, Rothenbacher D, Winkelmann BR. G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus. Circulation 2004;109:2844-9.

 

März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 2004;25:2109-19.

 

März W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, Winkelmann BR. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary disease: the Ludwigshafen risk and cardiovascular study. Circulation 2004;9:3068-74.

 

Martin P, Haefeli WE, Martin-Facklam M. A drug database model as a central element for computer-supported dose adjustment within a CPOE system. JAMIA 2004;11:427-32.

 

Martin-Facklam M, Rieger K, Riedel K-D, Burhenne J, Walter-Sack I, Haefeli WE. Undeclared exposure to St. John's Wort in hospitalized patient. Br J Clin Pharmacol 2004;58:437-41.

 

Martin-Facklam M, Kostrzewa M, Martin P, Haefeli WE. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil. Br J Clin Pharmacol 2004;57:80-5.

 

Mikus G, Schmidt L, Burhenne J, Ding R, Riedel K-D, Tayrouz Y, Weiss J, Haefeli WE. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet 2004;43:1015-24.

 

Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel K-D, Müller O, Hoppe-Tichy T, Haefeli WE, Mikus G, Walter-Sack I. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 2004;60:709-15.

 

Rengelshausen J, Lindenmaier H, Cihlar T, Walter-Sack I, Haefeli WE, Weiss J. Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem Biophys Res Commun 2004;320:90-4.

 

Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, März W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004;22:2398-400.

 

Riedel K-D, Rieger K, Martin-Facklman M, Mikus G, Haefeli WE, Burhenne J. Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry. J Chromatogr B 2004;813:27-33.

 

Rieger K, Scholer A, Arnet I, Peters FT, Maurer HH, Walter-Sack I, Haefeli WE, Martin-Facklam M. High prevalence of unknown co-medication in hospitalised patients. Eur J Clin Pharmacol 2004;60:363-8.

 

Romerio SC, Linder L, Nyfeler J, Wenk M, Litynski P, Asmis R, Haefeli WE. Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults. Atherosclerosis 2004;176:337-44.

 

Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz JR, Kappenberger L, März W, Vassalli G. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004;25:1438-46.

 

Simeoni E, Hoffmann MM, Winkelmann BR, Ruiz J, Fleury S, Boehm BO, März W, Vassalli G. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetology 2004;47:1574-80.

 

Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 2004;66:132-9.

 

Troost J, Albermann N, Haefeli WE, Weiss J. Cholersterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem Biophys Res Comm 2004;316:705-11.

 

Vassalli G, Winkelmann BR. Molecular genetics of myocardial infarction: many genes, more questions than answers. Eur Heart J. 2004;25:451-3.

 

Walter-Sack I, Clanget Ch, Ding R, Göggelmann Ch, Hinke V, Lang M, Pfeilschifter J, Tayrouz Y, Wegscheider K. Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin Pharmacokinet 2004;43:1037-53.

 

Weiss J, Haefeli WE. Genotyping of the A6986G polymorphism of CYP3A5. (letter) Br J Clin Pharmacol 2004;57:663-4.

 

Winkelmann BR. American heart association scientific sessions. Expert Opin Investig Drugs. 2004;13:435-45.

Publikationen 2003

Publikationen 2003

Bugert P, Hoffmann MM, Winkelmann BR, Vosberg M, Jahn J, Entelmann M et al. The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart disease. J Mol Med 2003;81:495-501.

 

Burhenne J, Riedel K-D, Martin-Facklam M, Mikus G, Haefeli WE. Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. J Chromatography B 2003;784:233-42.

 

Fröhlich M, Mühlberger N, Hanke H, Imhof A, Döring A, Pepys MB, Koenig W. Markers of inflammation in women on different hormone replacement therapies. Ann Med 2003;35:353-61.

 

Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003;24:1365-72.

 

Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine, and paramethoxyamphetamine. Addict Biol 2003;8:413-8.

 

Rengelshausen J, Göggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003;56:32-8.

 

Schneider V, Henschel V, Tadjalli Mehr K, Mansmann U, Haefeli WE. Impact of serum creatinine measurement error on dose adjustment in renal failure. Clin Pharmacol Ther 2003;74:458-67.

 

Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and cremophor RH40. Clin Pharmacol Ther 2003;73:397-405.

 

Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol 2003;55:191-8.

 

Walter-Sack I, Rittner Ch. Probandenversicherung nach dem Gefährdungsprinzip auch bei Forschungsvorhaben am Menschen ohne bisherige Versicherungspflicht - Vorschläge für eine Risikobewertung. VersR 2003;10:432-5.

 

Weiss J, Albermann N. Quantification of mRNA levels with reverse transcription-polymerase chain reaction (letter). Biochem Biophys Res Commun 2003;311:561-2.

 

Weiss J, Kerpen CJ, Lindenmaier H, Dormann S-MG, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003;307:262-7.

 

Weiss J, Haefeli WE, Gasse C, Hoffmann MM, Weymann J, Gibbs S, Mansmann U, Bärtsch P. Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt Med Biol 2003;4:355-66.

 

Weiss J, Hesse C, Haefeli WE. Rapid and reliable genotyping of the C181T polymorphism in the bradykinin B2 receptor gene. Clin Chem Lab Med 2003;41:281-3.

 

Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204.

 

Winkelmann BR. Pharmacogenomics, genetic testing and ethnic variablity: tackling the ethical questions. Pharmacogenomics 2003;4:531-5.

 

Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K, Judson Boehm BO, Tall AR, Ruano G, Marz W. Hyplotypes of the cholesteryl ester transfer protein gene predict lipd-modifying response to statin therapy. Pharmacogenomics J 2003;3:284-96.

 

 

Buchbeiträge

Haefeli WE. Arzneimittelverabreichung in der Notfallmedizin. In: Gyr NE, Schoenenberger RA, Haefeli WE, editors. Internistische Notfälle. 7th ed. Stuttgart New York: Georg Thieme Verlag; 2003.

 

 

Herausgebertätigkeit

Gyr NE, Schoenenberger RA, Haefeli WE, editors. Internistische Notfälle. 7th ed. Stuttgart New York: Georg Thieme Verlag; 2003.

Publikationen 2002

Publikationen 2002

Ammon S, Marx C, Behrens C, Hofmann U, Mürdter T, Griese EU, Mikus G. Diclofenac does not interact with codeine metabolism in vivo: A study in healthy volunteers. BMC Clinical Pharmacology 2002;2:2.

 

Gröbner W, Walter-Sack I. Hyperurikämie und Gicht - Diagnostik / Der konkrete Fall / Therapie. Dtsch Med Wochenschr 2002;127:207-13.

 

März W, Winkelmann BR. Akutes Koronarsyndrom - früher Einsatz von Statinen. Cardiovas 2002;1:68-9.

 

März W, Winkelmann BR. HMG-CoA reductase inhibition in the treatment of atherosclerosis: effects beyond lipid lowering. J Kardiol 2002;9:284-94.

 

Mansmann U, Winkelmann BR. Classification and prediction in pharmacogenetics - context, construction and validation. Pharmacogenomics 2002;3:157-60.

 

Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, Haefeli WE. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophore EL. Br J Clin Pharmacol 2002;53:576-81.

 

Martin-Facklam M, Kostrzewa M, Schubert F, Gasse C, Haefeli WE. Quality markers of drug information on the internet. An evaluation of sites on St. John's Wort. Am J Med 2002;113:740-5.

 

Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, Prange HW, Gleiter Ch, Brockmöller J. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002;54:592-603.

 

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med 2002;80:507-13.

 

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen risk and cardiovascular health (LURIC) study. Am J Cardiol 2002;90:1249-52.

 

Oettel M, Hübler D, Winkelmann BR. Über das therapeutische Potential von Estrogenen beim Mann. J Menopause 2002;2:39-51.

 

Ranjith N. Verho NK, Verhoe M, Winkelmann BR. Acute myocardial infarction in a young South African Indian-based population. patient characteristics on admission and gender-specific risk factor prevalance. Curr Med Res Opin 2002;18:242-8.

 

Rengelshausen J, Hull WE, Schwenger V, Göggelmann Ch, Walter-Sack I, Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 2002;39:E10.

 

Schwenger V, Mündlein E, Dagrosa EE, Fahr AM, Zeier M, Mikus G, Andrassy K. Treatment of life-threatening multiresistant staphyloccocal and enterococcal infections in patients with end-stage renal failure with Quinupristin/Dalfopristin: prelimiary report. Infection 2002;30:257-61.

 

Walter-Sack I. Unsicherheiten bei pädiatrischen Studien und Konflikte des Prüfarztes. DZKF 2002;3/4:6.

 

Walter-Sack I, Haefeli WE. Rahmenbedingungen ärztlicher Forschung beim Menschen - Algorithmen zu Planung und Organisation. Dtsch Med Wochenschr 2002;127:627-33.

 

Weiss J, Burhenne J, Riedel KD, Haefeli WE. Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS 2002;16:674-6.

 

Weiss J, Fricker R, Haefeli WE. Rapid detection of polymorphisms of the nitric oxide cascade. Clin Chem Lab Med 2002;40:341-4.

 

Winkelmann BR, Hoffmann MM, Lindenmaier H. Molekularbiologische Terminologie. Medizin im Dialog 2002;2:26-31.

Publikationen 2001

Publikationen 2001

Falconnier AD, Haefeli WE, Schoenenberger RA, Surber Ch, Martin-Facklam M. Drug Dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med 2001;16:369-375.

 

Ganßmann B, Klingmann A, Burhenne J, Tayrouz Y, Aderjan R, Mikus G. Simultaneous determination of loperamide and its demethylated metabolites in plasma and urine by high pressure liquid chromatography - atmospheric-pressure ionization mass spectrometry. Chromatographia 2001;53:656-60.

 

Gasse C, Hense H-W, Stieber J, Döring A, Liese AD, Keil U. Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertension 2001;15:27-36.

 

Khanlari B, Linder L, Haefeli WE. Local effect of transdermal isosorbide dinitrate (SDN) ointment on hand vein diameter. Eur J Clin Pharmacol 2001;57:701-4.

 

Loehrer FMT, Tschöpl M, Angst CP, Litynski P, Jäger K, Fowler B, Haefeli WE. Disturbed ratio of erythrocyte and plasma S-adenosylmethionine / S-adenosylhomocysteine in peripheral arterial occlusive disease. Atherosclerosis 2001;154:147-54.

 

Mikus G, Kees F. Die Substanz Buprenorphin aus pharmakologischer Sicht. Onkologie Service aktuell 2001;3:8-9.

 

Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001;161:2021-6.

 

Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001;70:405-14.

 

Walter-Sack I, Haefeli WE. Arzneimittelsicherheit auch für Kinder. Deutsches Ärzteblatt 2001;98:A447-9.

 

Webb JA, Rostami-Hodjegan A, Abdul-Manap R, Hofmann U, Mikus G, Kamali F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br J Clin Pharmacol 2001;52:35-44.

 

Winkelmann BR, Boehm BO, Nauck M, Kleist P, März W, Verho NK, Ranjith N, Kneissl G. Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in non-diabetic individuals with coronary artery disease. Curr Med Res Opin 2001;17:132-141.



Buchbeiträge

Haefeli WE. Therapie-Monitoring, Probleme der Compliance und Non-Compliance. In: Lemmer B, Brune K (Hrsg). Pharmakotherapie. München: Urban & Fischer Verlag; 2001, S. 20-8.

 

Haefeli WE, Arnet I. Gründe für fehlende Arzneimittelwirkung. In: Grundlagen der Arzneimitteltherapie. Basel: DOCUMED AG; 2001, S. 51-7.

 

Haefeli WE, Follath F, Biollaz J. Konzentrationsmessung von Arzneimitteln (Therapeutic Drug Monitoring). In: Grundlagen der Arzneimitteltherapie. Basel: DOCUMED AG; 2001, S. 29-37.

 

Martin-Facklam M. Pharmakokinetische Daten für die Dosisanpassung bei Nierenfunktionsstörungen. In: Grundlagen der Arzneimitteltherapie. Basel: DOCUMED AG; 2001, S. 13-28.

 

Martin-Facklam M, Haefeli WE. Klinisch relevante Entzugssyndrome. In: Grundlagen der Arzneimitteltherapie. Basel: DOCUMED AG; 2001, S. 214-8.

 

Martin-Facklam M, Wolf P. Informationsbeschaffung. In: Grundlagen der Arzneimitteltherapie. Basel: DOCUMED AG; 2001, S. 284-91.

 

Walter-Sack I, Gröbner W: Purinstoffwechsel, Urikostatika, Urikosurika. Pharmakotherapie der Gicht. In: W. Forth, D. Henschler, W. Rummel, U. Förstermann, K. Starke (Hrsg) Allgemeine und Spezielle Pharmakologie und Toxikologie, 8., völlig neu bearbeitete Auflage, Urban und Fischer München, 2001, S. 625-35.

Publikationen 2000

Publikationen 2000

Ammon S, Richter von O, Hofmann U, Thon K-P, Eichelbaum M, Mikus G. In vitro interaction of codeine and diclofenac. Drug Metab Disp 2000;28:1149-52.

 

Arnet I, Haefeli WE. Merkmale der offensichtlichen Non-Complier im Spital. Managed Care 2000;6:26–28.

 

Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle interpretation. Clin Pharmacol Ther 2000;67:44-7.

 

Drewe J, Ball HA, Beglinger C, Peng B, Kemmler A, Schächinger H, Haefeli WE. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Brit J Clin Pharmacol 2000;50:237-46.

 

Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000;20(6):629-34.

 

Gross AS, Eichelbaum M, Mörike K, Mikus G. Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. Br J Clin Pharmacol 2000;49:132-8.

 

Haefeli WE. Individualisierte Arzneimitteltherapie - es gibt etwas zu verbessern. Therapeutische Umschau 2000;57:545-6.

 

Hotz MA, Ritz R, Linder L, Scollo-Lavizzari G, Haefeli WE. Auditory and electroencephalographic effects of midazolam and ·-hydroxy-midazolam in healthy subjects. Br J Clin Pharmacol 2000;49:72-9.

 

Li S, Schänzle G, Hofmann U, Mikus G: Determination of morphine-3-glucuronide and morphine-6-glucuronide in human serum and urine using high-performance liquid chromatography with ultraviolet and eletrochemical detection. Analytical Pharmacology 2000;1:65-70.

 

Martin-Facklam M, Drewe J, Haefeli WE. Arzneimittel-Interaktion am Cytochrom-P450-System. Deutsch Med Wschr 2000;125:63-7.

 

Martin-Facklam M, Haefeli WE. Unerwünschte, klinisch relevante Arzneimittelinteraktionen. Therapeutische Umschau 2000;57:579-83.

 

Martin-Facklam M. Individualisierung der Arzneimitteltherapie bei Nieren- und Leberinsuffizienz. Therapeutische Umschau 2000;57:568-72.

 

Mikus G. Klinische Relevanz von Polymorphismen des Arzneimittelstoffwechsels. Therapeutische Umschau 2000;57:573-8.

 

Müller-Schweinitzer E, Brett W, Zerkowski H-R, Haefeli WE. The mechanism of cryoinjury: In vitro studies on human internal mammary arteries. Br J Pharmacol 2000;130:636-40.

 

Rittner Ch, Kratz EJ, Walter-Sack I. Zur Angemessenheit des Probandenschutzes nach § 40 Abs. 1 Nr. 8 AMG. - Bericht der Arbeitsgruppe "Probandenversicherung" des Arbeitskreises Medizinischer Ethikkommissionen. VersR 2000;16:688-94.

 

Romerio SC, Linder L, Flammer J, Haefeli WE. Correlation between apoliprotein B and endothelin-1-induced vasoconstriction in humans. Peptides 2000;21:871-4.

 

Salbach PB, Brückmann M, Turovets O, Kreuzer J, Kübler W & Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Brit J Clin Pharmacol 2000;50:221-6.

 

Schwaninger M, Ringleb P, Annecke A, Winter R, Kohl B, Werle E, Fiehn W, Rieser PA, Walter-Sack I. Elevated plasma concentrations of lipoprotein (a) in medicated epileptic patients. J Neurol 2000;247:687-90.

 

Schwarz S, Knauth Michael, Schwab S, Walter-Sack I, Bonmann E, Storch-Hargenlocher B. Acute disseminated encephalomyelitis after parenteral therapy with herbal extracts: a report of two cases. J Neurol Neurosurg Psychiatry 2000;69:516-8.

 

Walter-Sack I, Haefeli WE. Berücksichtigung der Arzneimittelabsorption in der Individualisierung der Arzneimitteltherapie. Therapeutische Umschau 2000;57:557-62.

 

Walter-Sack I, Haefeli WE. Qualitätssicherung der pädiatrischen Arzneimittel–Therapie durch klinische Studien - ethische und rechtliche Rahmenbedingungen unter Berücksichtigung der spezifischen Bedürfnisse von Kindern. MedR 2000;10:454-3.

 

 

Publikationen 1999

Publikationen 1999

Arnet I, Schoenenberger RA, Spiegel R, Haefeli WE. Überzeugungen als Fundament der Compliance und Techniker der Patienten zur Compliance-Optimierung. Schweiz Med Wschr 1999;129:1477-86.

 

Rätz AE, Schlienger RG, Linder L, Langewitz W, Haefeli WE. Pharmacokinetics and pharmacodynamics of clomethiazole after oral and rectal administration in healthy subjects. Clin Ther 1999;21:829-40.

 

Romerio SC, Linder L, Haefeli WE. Neurokinin 1-receptor antagonist R116301 inhibits substance P-induced venodilation. Clin Pharmacol Ther 1999;66:522-7.

 

Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest 1999;29:1003-9.

 

 

 

Poster

Poster

Gottwalt K, Hohmann N, Carls A, Czock D, Haefeli WE, Mikus G. Steady-state plasma concentrations during a continuous infusion of microgram doses of the CYP3A Marker substrate midazolam in healthy volunteers. Naunyn-Schmiedeberg’s Arch Pharmacol 2015; 388(Suppl1):51.

 

Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Pharmacokinetics of an Intravenous Microgram Dose of Midazolam. Clin Pharmacol Ther 2014; 95 (suppl.1): S45.

 

Reinhard R, Hohmann N, Carls A, Burhenne J, Mikus G, Haefeli WE. No pharmacokinetic drug interaction between the novel NNRTI rilpivirine and the CYP3A probe drug midazolam. Naunyn-Schmiedeberg’s Arch Pharmacol 2015;388(Suppl1):56.

 

Ziesenitz V, Skopp G, König S, Burhenne J, Mahlke N, Mikus G. Pharmacokinetic interaction between the opioid-analgesic Fentanyl and the CYP3A inhibitor Ketoconazole. Presented at PAINWEEK 2011, September 7-10, 2011, Las Vegas, Nevada, U.S.A.

 

Ziesenitz V, König S, Weiss J, Burhenne J, Mikus G. Midazolam is not a substrate of Hepatic Organic Anion-Transporting Polypeptide 1B1. Br J Clin Pharmacol XX suppl.1, YY (2011).

 

Ziesenitz V, Mahlke N, Koenig S, Skopp G, Weiss J, Haefeli WE, Mikus G. Effect of OATP inhibition by rifampicin on the pharmacokinetics of fentanyl in healthy volunteers genotyped for organic anion transporting polypeptide 1B1. Clin Pharmacol Ther 91 suppl. 1, S61-2 (2012).

 

Ziesenitz V, König S, Weiss J, Burhenne J, Haefeli WE, Mikus G. Midazolam pharmacokinetics are not influenced by polymorphisms of hepatic OATP1B1 in healthy volunteers. Clin Pharmacol Ther 91 suppl. 1, S61 (2012).

Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen